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CHAPTER 1 INTRODUCTION & BACKGROUND 
1.1 Basics of Radiotherapy 
Radiation has been shown consistently capable of destroying cancer cells.  For this 
reason it is often used for the treatment of tumors.  Most often this treatment involves the firing 
of high energy photons (a particle of electromagnetic radiation) out of a linear accelerator (linac) 
at the target region of interest.  A sample linear accelerator is displayed in Fig. 1.  The amount 
of radiation delivered to a patient is defined as dose and measured in units of Gray (Gy).  
Because radiation is dangerous to not only cancer cells, but also healthy tissue, the radiation 
field is shaped to the target of interest to minimize the quantity of harmful radiation from 
reaching healthy tissues.  This shaping is done using primary collimators as well as multi-leaf 
collimators (MLCs).  Primary collimators, also called jaws, are large heavy metal blocks that 
create a rectangular or square radiation field of a certain size.  MLCs are tungsten leaves such 
as those found in Fig. 2 which move back and forth to block unnecessary radiation from 
reaching healthy tissues.  MLCs can be used to create irregularly shaped fields that accurately 
deliver dose to the tumor while minimizing dose to healthy tissue. 
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Figure 1 An Elekta Infinity linear accelerator 
 
 
Figure 2.  A multi-leaf collimator (MLC) shapes the radiation field 
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 Two common methods (modalities) for radiotherapy are intensity modulated 
radiotherapy (IMRT) and volumetric modulated arc radiotherapy (VMAT).  IMRT sub-
modalities include step-and-shoot and sliding-window.  For step-and-shoot IMRT, radiation is 
only turned on when the leaves are stationary.  Leaves are moved into new orientations while 
radiation is off.  For sliding-window IMRT, leaves are allowed to move while radiation is turned 
on.  This allows for radiation to more precisely conform to the target.  VMAT is similar to 
IMRT except that the treatment head rotates around the patient and dose rate is adjustable during 
delivery.  This allows conformal target doses to be delivered in a relatively shorter period of 
time.  Depending on the treatment site and prescribed dose, VMAT may also reduce toxicity 
probabilities. 
Every patient’s tumor shape and anatomy are different.  Thus, every patient requires an 
individual treatment plan.    A treatment plan is defined by the mechanical orientation of the 
MLCs and jaws as well as the amount of radiation being delivered (monitor units (MU)) and 
the orientation of the treatment head (gantry angle).  The treatment plan is comprised of a 
sequence of control points containing each of these machines parameters.  As the treatment is 
delivered, the MLC/collimators moves, the gantry rotates, and MU is outputted according to 
these control points. 
1.2 Treatment Planning Optimization 
Treatment planning optimization is an iterative process in which the aforementioned 
machine parameters are determined so as to achieve a desired dose distribution that uniformly 
covers the tumor with the prescribed dose while minimizing dose to healthy tissue.  The 
treatment planning system (TPS) used in this study was Pinnacle3 by Philips.  The optimization 
algorithm utilized herein as part of Pinnacle3 is a sequential quadratic programming (SQP) 
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optimization algorithm from the NPSOL library.1 The dense SQP algorithm utilizes gradient 
descent to achieve progressively more optimal treatment plans.2,3  During each iteration, the 
following steps are carried out: (1) a machine parameter is changed; (2) a 3D dose distribution 
is calculated for the new plan; and (3) the quality of the new plan is assessed.  For step 2, dose 
is calculated using a dose calculation method.  Two dose calculation methods are assessed as 
part of this study and will be introduced shortly.  For step three, plan quality is assessed using 
a dose objective function.  Put simply, a dose objective function is a series of dose-volume 
objectives that the plan should ideally meet.  These dose-volume objectives are best explained 
in terms of dose-volume histograms (DVHs).  Sample DVH curves are plotted in Fig. 3.  Each 
curve displays how much dose is delivered to each structure.  Specifically, DVHs display what 
percentage of each structure receives how much dose. 
 
Figure 3  A sample dose-volume histogram (DVH) shows what percent volume of the regions of interest 
(ROIs) receive what percentage of the prescription dose.   
 
 A volume greater than the tumor itself is treated.  The tumor itself is labeled the gross 
tumor volume (GTV).   A margin of expansion is utilized to account for any nearby microscopic 
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cancer involvement as well as any regional involvement (e.g. lymph nodes).  This expanded 
volume is labeled the clinical target volume (CTV).  The internal target volume (ITV) is the 
CTV expanded by a margin that accounts for any intra-treatment tumor motion due to patient 
motion.  Lastly, the planning target volume (PTV) is the ITV expanded by some margin to 
account for any potential setup errors.  The prescribed dose is delivered to the PTV to assure 
that the CTV receives the prescribed dose. 
1.3 Dose Calculation Methods 
 Dose calculation methods are responsible for accurately calculating the dose delivered 
to the patient.  The two main parts of a dose calculation method are the dose calculation 
algorithm and the beam model.  In general, there are three types of dose calculation algorithms: 
(1) convolution-superposition, (2) Monte Carlo, and (3) Boltzmann Solvers.  Generally 
speaking, convolution-superposition (CS)-based algorithms are fast but less accurate while 
Monte Carlo (MC) and Boltzmann Solver-based algorithms are slower but more accurate.  CS-
based algorithms are most commonly used, however, as computers become increasingly faster, 
Monte Carlo and Boltzmann Solver are also becoming increasingly common.  Two calculation 
algorithms were assessed as part of this study.  First, Pinnacle3’s collapsed-cone convolution-
superposition algorithm was assessed.  This is the algorithm that our institution is currently 
utilizing as part of treatment planning optimization.  Second, ScientificRT’s SciMoCa Monte 
Carlo algorithm was assessed.  Unfortunately, Monte Carlo is still too slow to be routinely used 
in treatment planning and optimization, therefore, SciMoCa is utilized to verify the accuracy of 
CS dose calculation.  Boltzmann Solver algorithms are introduced but are not an important part 
of this study. 
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Each brand of linac, each model of linac, and each individual linac is constructed 
differently.  These differences mean that every linac must be modelled individually.  
Furthermore, every commissioned linac energy must also have its own beam model.  This 
means every linear accelerator may have 2-3 beam models.  Every treatment planning system 
(TPS) utilizes a slightly different beam modelling process, but largely speaking these 
parameters are consistent for each type of dose calculation algorithm.  For instance, CS beam 
modeling parameters include values of MLC and collimator transmission, minimum leaf 
separation, effective source size, quantification of electron contamination, and many other 
factors.  In order to set these beam modelling parameters, a wide variety of dose measurements 
are taken in a water tank.  Beam modelling parameters are set so that the resultant calculated 
doses match the measured doses as accurately as possible.  It is important to understand that 
dose calculation accuracy is not only dependent on the inherent dose calculation accuracy of an 
algorithm (e.g. CS or MC), but also dependent on a high quality beam model which is able to 
accurately calculate dose for a wide range of clinical cases.  It follows that any differences in 
dose between CS and MC may be due to inherent differences in the calculation algorithms or 
may simply be due to poor beam modelling.  Whereas the prior type of dose difference is 
unavoidable, the latter dose difference is fully avoidable.  When evaluating MC vs. CS dose 
differences in this study, differences will be evaluated as avoidable or unavoidable.  This step 
is critical from the perspective of treatment planning QA.   
1.3.1. Monte Carlo 
 Task Group report of the AAPM 105 serves as a great introduction to the basics of 
Monte Carlo as well as current issues associated with the utilization of such algorithms.4 Monte 
Carlo is a statistical simulation method for calculating dose that relies on physical principles of 
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radiation transport in matter.  In Monte Carlo, a large (~108) number of particle histories are 
simulated and recorded.  For example, let a photon be generated and fired at the patient of 
interest.  Using physical interaction probabilities, the distance to interaction as well as 
interaction type can be determined.  The particle is then transported to the interaction site and 
the interaction simulated.  These steps are repeated until all secondary particles leave the dose 
grid or deposit all of their energy (E < pre-specified energy threshold).  In Monte Carlo, 
quantities of interest are recorded over a vast numbers of particle histories.  The statistical 
average of their cumulative effects is utilized to calculate the dose delivered to the patient. 
 The Monte Carlo algorithm utilized by this study was ScientificRT’s SciMoCa 
algorithm.  SciMoCa shares its fundamental concept with the voxel Monte Carlo (VMC) family 
of codes, e.g. VMC++ or XVMC.5-7 SciMoCa is also based off a more recent series of papers 
by Sikora et al.8-9 The beam model utilized is not clinically commissioned and is currently used 
for research purposes only.  For all calculations, unless otherwise stated, particle histories are 
simulated to achieve 1% dosimetric variance at 70% max dose.  
1.3.2. Convolution-Superposition 
 Convolution-superposition dose calculation was introduced by Thomas Mackie in 
1984.11-13 The algorithm allows for the calculation of 3-dimensional (3D) dose in heterogeneous 
patient anatomies for irregular field sizes.  The basic process of CS is as follows.  First, a Monte 
Carlo kernel is calculated.  This kernel, displayed in Fig. 4 represents how radiation will deposit 
its energy in the patient or some medium relative to the interaction voxel (in bold).  CS utilizes 
two of these Monte Carlo kernels.  The first is the primary kernel which accounts for dose 
deposition for primary radiation – radiation originating from the target or source.  The second 
is the scatter kernel which accounts for dose deposited by secondary/scattered radiation – 
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radiation originating from attenuated primary radiation.  These kernels then undergo the process 
of convolution superposition.  The easiest way to think of convolution-superposition is as 
follows.  Every voxel in the patient or phantom is going to have some amount of primary and 
secondary radiation interaction occur in it – this quantity is the photon fluence.  However, the 
dose from this interaction is not deposited entirely in the interaction voxel.  Rather, the dose is 
deposited in surrounding voxels in accordance with the kernels.  By considering every voxel in 
the patient as an interaction voxel, tracking the dose deposition to all other voxels using these 
kernels, and summing all of these doses, a 3D dose distribution is acquired. 
 
Figure 4  Monte Carlo calculated primary dose spread arrays.  The numbers represent the dose deposited 
in the voxel normalized to the collision KERMA in the interaction voxel.  
 
  There are several sub-types of convolution-superposition algorithms.  The CS 
algorithm utilized herein was Pinnacle3’s collapsed-cone convolution-superposition algorithm.  
Collapsed-cone was introduced in 1988 by Anders Ahnesjo as a means of reducing the 
computational cost of standard convolution-superposition algorithms.14 One of the key 
differences of collapsed-cone CS is that it utilizes an analytical Monte Carlo kernel calculated 
using Eq. 1, where Aθ, aθ,, Bθ, and bθ are functions of the scattering angle θ and the beam energy 
acquired from pre-calculated lookup tables.  The first term accounts for primary dose while the 
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second term accounts for secondary dose.  It follows that dose can be calculated using Eq. 2 
where D is the dose, f is a depth hardening correction factor, T is an approximate TERMA 
distribution, ρ is the medium density, and h is the poly-energetic kernel.  The variables r and s 
correspond to the dose-deposition and interaction voxels respectively.  The computational cost 
of this integral is O(N6), where N is the number of voxels along one side of the dose grid.  
However, by discretizing space into a spherical coordinate system, this computational cost can 
be greatly deduced.  Using a spherical coordinate system (l,m,n) comprised of conical shell 
segments of solid angle Ωmn around Θm, φn, and of thickness Δr, dose can instead be calculated 
using Eq. 3. Let η be a spatially varying function of the heterogeneous medium density.  The 
radiant primary energy along the line through all segments on the line is calculated via recursion 
one voxel segment at a time as in Eq 4.  Using this formalism, dose is instead calculated in 
O(M∙N3) where M is the number of cones.  This is a huge speedup and the key advantage over 
collapsed-cone convolution-superposition over standard convolution-superposition algorithms. 
𝒉𝒘(𝒓, 𝜽) =
(𝑨𝜽𝒆
−𝒂𝜽𝒓+ 𝑩𝜽𝒆
−𝒃𝜽𝒓)
𝒓𝟐
     (1) 
 
𝑫(𝒓) =
𝒇(𝒓)
𝝆(𝒓)
∭ 𝑻(𝒔)𝝆(𝒔)𝒉(𝒔, 𝒓)𝒅𝟑𝒔        (2) 
 
𝑫(𝒓) =  
𝜼(𝒓)
𝝆(𝒓)
𝟏
𝒅𝟐𝒖
∑ ∑ [𝒂𝒎𝑹𝒎𝒏
𝒑 (𝒓) +  𝒃𝒎𝑹𝒎𝒏
𝒔 (𝒓)]𝒏𝒎                  (3) 
 
𝑹𝒎𝒏
𝒔 (𝒓𝒊) = 𝑹𝒎𝒏
𝒔 (𝒓𝒊−𝟏)(𝟏 − 𝒃𝒎𝜼𝒊𝜟𝒓) +  𝑻𝒊𝝆𝒊𝜴𝒎𝒏𝒅
𝟐𝒖
𝑩𝒎
𝒃𝒎
𝜟𝒓  (4) 
1.3.3 MC vs CS  
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 As stated recently, the primary difference between MC and CS is speed versus accuracy.  
The loss of accuracy in CS (with respect to MC) is primarily seen in two circumstances.  The 
first inadequacy of CS is when the patient anatomy is particularly heterogeneous.  Arnfield et 
al. showed differences in Monte Carlo (PEREGRINE) vs. collapsed-cone convolution-
superposition as large as 10% in a heterogeneous lung phantom for a 4x4 cm2 square field.15 
The effects of heterogeneity on Monte Carlo and collapsed-cone calculated doses will be further 
assessed as part of this study.  The second inadequacy of CS is when the treatment plan is 
comprised of many small segments.  Zhao et al. showed collapsed-cone CS consistently over-
estimated PTV dose by 5% compared to MC.16 Zhen et al. showed collapsed-cone was 3-4% 
higher for IMRT and VMAT plans than Accuros XB’s (AXB) Boltzmann Solver algorithm.17 
For reference, AXB is typically considered similar in accuracy to Monte Carlo.18 For each of 
these publications, collapsed-cone is shown to over-estimate target dose for complicated IMRT 
and VMAT fields.  The effect of beam complexity on this discrepancy will be analyzed as part 
of this study. 
 Dose differences (MC vs. CS) due to heterogeneity are a result of inherent differences 
in the calculation algorithms.  CS is known to do a poor job of calculating dose in heterogeneous 
patient anatomies.19 This is because the Monte Carlo kernels utilized by CS are calculated in a 
homogeneous water phantom.  When heterogeneous (non-water) voxels are present, CS 
accounts for patient heterogeneity using range scaling.  In range scaling, the average mass 
density of voxels between the interaction and dose-deposition voxels is calculated and utilized 
when extracting values from the kernels.  For single-scattered photons, dose deposition can 
only occur exactly on the line between the interaction and dose deposition voxels.  Therefore, 
the range scaling approximation correction factor is perfectly accurate.  However, for multiple-
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scattered photons, they will likely have interacted in voxels not directly between the interaction 
and deposition voxels.  As a result, the range scaling approximation factor will not be perfectly 
correct.  It is important to note that for multiple-scatter photons, the mean density of the entire 
patient/phantom is utilized instead of the mean density between the interaction and deposition 
voxels.  This is done for two reasons.  First, photons do not necessarily interact only in voxels 
between the interaction and deposition voxels.  Second, this approximation reduces the 
computational cost of the dose calculation.  In comparison, MC physically models the 
interactions of particles (photons, electrons, positrons) in matter, thus allowing it to accurately 
model the interaction of these particles in heterogeneous anatomies. 
 For CS and collapsed-cone CS algorithms, dose is calculated per control point, where a 
control point is a planning parameter that defines the linac state (collimation positions, delivered 
MU, gantry angle) at some point in the planned treatment delivery.  For example, a VMAT 
delivery might utilize a 4° control point spacing.  This means that the collimator positions and 
MU output are defined every 4°.  Dose is calculated at each of these discrete gantry angles.  
However, radiation is being outputted continuously along all gantry angles in the VMAT arc, 
not at discrete angles.  In comparison, MC simulates particle histories continuously at all 
possible gantry angles.  Thus, whereas the collapsed-cone algorithm investigated herein is 
susceptible to dose differences due to gantry discretization, MC is not. 
1.4 Treatment Planning QA 
 There exist many sources of dosimetric error and uncertainty.  It is the goal of 
radiotherapy QA to ensure that dosimetric accuracy falls within some maximum permissible 
level.  If the difference between measured dose and expectation varies by more than this 
maximum permissible level, or action tolerance, then some action should be taken to rectify the 
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problem.  The most commonly cited conclusion is that end-to-end dosimetric accuracy should 
be within ±5%.20-22 However, ultimately what matters is not the delivered dose, but adequate 
control of the tumor as well as acceptable values of normal tissue complication probability 
(NTCP).  Tumor control probability (TCP) is a formalism that defines the probability that the 
tumor will be controlled given the prescription dose.  The TCP-formalism utilized in this study 
is the effective uniform dose (EUD)-based formalism developed by Niemierko et al.23 It can be 
calculated via Eq. 5 and Eq. 6 where EUD is the absorbed dose to the patient that when 
homogeneously given to a tumor yields the same number of surviving clonogenic cells as the 
actual heterogeneous dose distribution.  In Eq. 5, vi is the partial fraction of the target volume 
that receives dose Di.  The parameter ‘a’ is a tissue-specific parameter that models how the 
tumor or normal tissue of interest responds to inhomogeneous irradiation.  TCP is subsequently 
calculated from EUD where TCD50 is the homogeneous dose to the tumor that will result in a 
50% control rate.  γ50 is a tissue-specific model parameter that quantifies the slope of the dose-
response curve.  The dose response slope determines the percent variation in tumor control 
probability (TCP) per percent difference in target dose.  NTCP quantifies that probability that 
a dose of radiation to an organ at risk (OAR) will experience complications as a result of the 
prescribed dose.  NTCP can be calculated per Eq. 7 and Eq. 8. where TD50(V) is the tolerance 
dose that results in a 50% complication probability due to the partial, uniform irradiation of 
volume V.  The slope of the dose response curve is labeled m.  Literature recommends that end-
to-end dose accuracy should be within 5%20-22, however, realistically, required dosimetric 
accuracy will vary from case to case.  This is because the required accuracy will vary with the 
steepness/slope of the dose-response curve, γ50, as well as what is clinically achievable.  For 
instance, if γ50 is equal to 5.0, then TCP will drop by 5% per 1% decrease in target dose.  If γ50 
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is equal to 1.0, then TCP will only drop by 1% for a 1% decrease in target dose.  It follows that 
a site with a low γ50 value will not require as stringent of dose accuracy, whereas a site with a 
high γ50 value will require more stringent dose accuracy – perhaps 2 to 3%.  However, this level 
of accuracy is difficult to achieve.  In the remainder of section 1.4, the limit of what is clinically 
achievable is addressed within the scope of the following dosimetric uncertainties: machine 
calibration, patient positioning accuracy, ROI segmentation and target deformation, tumor 
motion, electron density calibration, and dose calculation.  All-together, the processes by which 
these dosimetric uncertainties are quantified and minimized is called treatment planning QA.  
Treatment planning QA is broadly described in TG-53.24   
𝑬𝑼𝑫 =  (∑ (𝒗𝒊𝑫𝒊
𝒂)𝒊 )
𝟏/𝒂          (5) 
𝑻𝑪𝑷 =  
𝟏
𝟏+ (
𝑻𝑪𝑫𝟓𝟎
𝑬𝑼𝑫
)
𝟒𝜸𝟓𝟎
           (6) 
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𝟐
⁄  𝒅𝒕
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           (7) 
𝐭 =  
𝑫−𝑻𝑫𝟓𝟎(𝑽)
𝒎 𝑻𝑫𝟓𝟎(𝑽)
                 (8) 
 The role of machine QA is to reduce systematic dosimetric uncertainties pertaining to 
the linac to within an acceptable limit.  Without properly managing daily, monthly, and yearly 
machine QA, significant dosimetric uncertainties can find their way into clinical treatment.  
Task Group reports 40 and 142 lay out recommendations for machine QA of linear 
accelerators.25,26 For IMRT cases, output constancy of the machine must be within 3% daily 
and 2% monthly.  Lasers must be aligned within 1.5mm daily and 1.0mm monthly.  In the 
monthly QA check, the radiation-light field coincidence, optical distance indicator (ODI), jaw 
positioning, and treatment couch positioning should all be within 1mm.  The gantry read out 
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must also be accurate within 1 degree of actuality.  Electron and photon beam profile constancy 
should be within 1% and electron beam energy constancy should be within 2%.  
 Correct patient positioning and immobilization ought to be assessed daily via image 
guidance (e.g. cone beam CT (CBCT)) to reduce any potential dosimetric uncertainties.  
Positioning uncertainty varies between treatment sites.  For stereotactic brain radiotherapy 
utilizing a head ring, expected uncertainty is 1mm.27 For breast and prostate radiotherapies 
utilizing a Vac-Lok, positioning uncertainty is expected to be 6mm and 2mm respectively.28,29 
Rotondo et al. shows that H&N positioning errors are typically a few millimeters.30 Kaur et al. 
goes on to show that PTV dose volume constraints (D2/50/95/98) vary by about 1% for H&N cases 
for setup errors of 1-2mm when using a 5mm PTV margin.31  Rudat et al. showed that TCP can 
drop by 5% and 11% respectively for esophageal and prostate cancers as a result of clinically 
relevant setup errors.32-33    
 The management of target motion has become increasingly important with the 
introduction of image-guided radiotherapy.  Intrafraction motions include respiratory, cardiac, 
and gastro-intestinal.  Tumor motion causes the CT to be distorted; the tumor and OARs are 
blurred over the full range of their motions.  Typically, the CTV is expanded by some margin 
to account for the full range of motion of the target, however, inadequate margins can result in 
under-dosing of the CTV.  For lung tumor treatment, without the use of a more advanced 
respiratory management technique, Machalakos et al. showed GTV D95, V95, and TCP all 
changed by about 1.3 ± 3.8% due to intra-fractional breathing motion; a patient-specific 1-2cm 
CTV-PTV margin was utilized.35 GTV dose difference for these metrics was as large as 10% 
for 4% of the treatment cases.  Given the significance of this dosimetric error, TG-91 addresses 
the management of respiratory motions using more advanced techniques.35 There exist multiple 
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more advanced methods for reducing the dosimetric uncertainties due to respiratory motion.  
The most common of these methods are respiratory gating, breath-hold, and abdominal 
compression.  In respiratory gating, the tumor motion is tracked during the actual treatment.  
Radiation is delivered when the tumor position is within a certain range.  Using a phase-based 
respiratory-gated 4D-CT technique, Lin et al. showed that dose differences to the PTV, bilateral 
lungs, and OARs were minimal.36 For deep inspiration breath-hold (DIBH), the patient is 
coached to inhale deeply and hold their breath so as to produce a reproducibly deep inhale 
during pre-treatment CT and treatment.  Using DIBH, Rosenzweig et al. showed PTV dose can 
be increased from 69Gy to 88Gy with no increase in NTCP values.37 By compression the 
patient’s abdomen, the patient’s breathing is forcefully minimized in order to reduce tumor 
motion.  This allows for reduced CTV-PTV margins and reduced NTCP rates.  Sarkar et al. 
shows lung NTCP rates can be reduced by 2% for both conformal and VMAT lung cancer 
treatment plans.38 In general, the dosimetric effects of respiratory motion is small when 
correctly accounted for using these techniques. 
 Accurate contouring of the GTV, CTV, and PTV volumes is necessary in order to 
adequately account for microscopic cancer spread, patient motion, and setup uncertainty.  
Accurate OAR contouring is necessary to accurately predict normal tissue complication 
probabilities (NTCP).  However, our ability to accurately delineate these structures suffers from 
inadequate training of dosimetrists, human error, and a lack of consensus in regard to how the 
planning volumes ought to be defined.39 In a study by Fiorino et al., inter-observer variability 
in rectum contouring resulted in dose differences of 3-4% (standard deviation).40  In a SRS study 
by Stanley et al., the median absolute difference in conformity index (CI) between reference 
contours of the metastases and alternative contours drawn by 8 other physicians was 0.35.41  
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Although DVH-based impacts were not assessed as part of this study, a mean absolute CI 
difference of 0.35 is large.  CI values can range from 0 to 1 (ideal coverage), so a difference of 
0.35 is very significant.   
 The patient’s anatomy is subject to change over the course of radiation treatment relative 
to the planning CT.  However, dose is only calculated on the pre-treatment planning CT.  Ideally, 
a new CT would be taken every day, a new daily-plan generated, and a new daily-dose 
calculated.  However, given current constraints of the clinical workflow this is not feasible.  
Instead, this new CT/plan/dose is only acquired when the change in the patient’s anatomy is 
large enough to warrant pushing the patient’s treatment back a day.  The dosimetric impact of 
anatomical variation can be significant.  For instance, van der Horst et al. showed that CTV D98 
coverage can drop by 10% due to inter-fractional tumor position variations.42 In the case of 
IMRT treatment of H&N cancer, Cheng et al. showed that reduction in the size of the target 
volume over the course of treatment often resulted in increased dose the spinal cord, brain stem, 
and parotid glands.43  For prostate cases treated using VMAT, Chow et al. showed that reduction 
in the size of the patient over the course of treatment yielded approximately a 2-3% increase in 
prostate and normal tissue dose per centimeter in reduction of the patient’s size (reduction 
measured in terms of depth of the tumor).44 In order to mitigate these dose discrepancies, several 
techniques have been developed.  These include cone-beam CT (CBCT), deformable image 
registration (DIR), and adaptive radiotherapy (ART).  These processes are not covered as they 
fall outside of the scope of this thesis. 
 CT images are 3D arrays of values which quantify the attenuability of radiation in matter 
relative to water and air.  This attenuability is quantified in Hounsfield Units (HU), also called 
CT number.  However, in dose calculation algorithms, calculation is based on the electron 
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density of each voxel, not the HU.  This is because the stopping power, or absorption rate, of 
electrons is dependent on the electron density of matter.  Thus, it is necessary to convert HU 
into electron density (ED).  This conversion is carried out using a CT-ED calibration curve.  
Any inaccuracies in this curve can potentially introduce dosimetric error into the treatment plan.  
Das et al. displays that CT-ED errors are more relevant for IMRT cases and for treatment sites 
with pronounced high-density bone present.45 For IMRT cases, dosimetric differences due to 
inaccurate CT parameters could be as high as 5% in the presence of bony anatomies. 
 Dose calculation accuracy is one of the greatest factors in the overall end-to-end 
dosimetric accuracy of the radiotherapy workflow.  Dose calculation accuracy depends partially 
on the inherent accuracies of the dose calculation algorithm, but also upon the quality of the 
measurement data that was used in the beam modeling as well as the accurate determination of 
beam model parameters in the treatment planning system.  Dose calculation accuracy in 
heterogeneous media needs to be thoroughly established.  The ability to accurately calculate 
dose for complex treatment fields also needs to be thoroughly vetted.  In section 1.3.3 the effects 
of heterogeneity were shown to cause local calculation differences on the order of 10%.  In the 
same section, collapsed-cone IMRT and VMAT fields were shown to consistently over-
estimate dose by approximately 3% relative to Monte Carlo dose calculation.17 
 The linear accelerator needs to be able to accurately deliver the treatment plan precisely.  
This includes accurate reproduction of field sizes, gantry angle, machine output, MLC 
positioning, etc.  A study by Moran et al. tabulates the accuracies of various delivery 
components as well as their corresponding dosimetric impacts.46 Collimator output factors are 
typically accurate within 0.5-1.0%.47 MLC positioning accuracy is typically less than 1mm, 
however the effect this error has on dose is highly dependent on the gap between adjacent 
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leaves.48  For example, Nithiyanantham et al. shows dosimetric errors can be as high as 6% per 
millimeter of MLC error for plans with steeper dose gradients.  The gross effect of leaf 
transmission errors can result in dose differences as high as 3% for poorer treatment models.49 
The table top must be accurately accounted for in the treatment planning system.  Not 
accounting for the table top, or accounting for it incorrectly can result in local dose differences 
as high as 10-15% at certain gantry angles.50  
 Although it is fairly easy to isolate each of these dosimetric uncertainties and quantify 
them separately, it is more difficult to evaluate their combined effects.  Furthermore, the effects 
of these dosimetric uncertainties will vary case to case.  So then how do we know if the 
dosimetric accuracy of each patient’s plan is within the ±5% limit that is required?  The best 
way to verify your treatment planning QA is to plan, treat, and measure dose as delivered to an 
anthropomorphic (heterogeneous anatomically-realistic) phantom.  The radiological physics 
center (RPC) at M.D. Anderson Cancer Center provides these anthropomorphic phantoms to 
institutions for the credentialing of linear accelerators.  After your institution has delivered a 
radiation treatment plan to the phantom, RPC evaluates the dose that was delivered to implanted 
TLD detectors to determine that your institution was able to properly deliver the specified 
radiation dose to the target while sparing surrounding tissues.  Molineu et al. analyzes the ability 
of 763 institutions to accurately deliver IMRT dose to an anthropomorphic head and neck (H&N) 
phantom.99 This data, acquired from 2001-2011, provides an idea of what is a clinically 
achievable measure of dose accuracy.  31% of the institutions failed to deliver dose to the target 
within ±5%.  A more recent study by et al. looks at data for the same H&N phantom but between 
November 2014 – October 2015.100 Results show that 77% of institutions were able to pass a 
5%/4mm gamma criteria.  50% of failures were due to systematically low delivered dose.  
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Although verifying your institution’s end-to-end dosimetric accuracy using an 
anthropomorphic phantom is ideal, such a phantom may not always be available. 
 Short of using an anthropomorphic phantom with implanted dosimeters, TG-119 is an 
apt commissioning test for verifying accurate dose.  TG-119 puts forth a variety of clinically 
relevant test cases which institutions can use to assess the accuracy of IMRT delivered dose.49 
It is the task of each institution’s physicists to create a treatment plan for each test case, irradiate 
a solid water stack in accordance with said treatment plan, measure the resultant dose at two 
pre-specified high dose and low dose points using an ion chamber, and calculate the percent 
difference in calculated and measured doses.  This commissioning test verifies that your 
treatment planning QA was effective.  Specifically, TG-119 verifies that your machine QA, 
machine delivery, and dose calculation are correct/accurate.  Because this test lacks an 
anthropomorphic phantom, these tests are incapable of verifying correct patient positioning, 
accurate accounting for patient heterogeneity, and an accurate CT-ED table.  This test also does 
not assess the correct handling of inter- and intra-fraction target motion.  TG-119 contains 
results for 10 institutions.  Dosimetric accuracy is reported as a confidence limit (the mean 
calculation error (relative to measurement) plus 1.96 times the standard deviation).51 On 
average, over all treatment sites and all institutions, confidence limits were 4.5% in high dose 
regions and 4.7% in low dose regions.  This data suggests that dosimetric differences greater 
than 5% occur about 5% of the time.  In comparison, RPC showed that dose difference was 
greater than 5% about 20% of the time.  This difference is attributed to the fact that TG-119 
utilizes a homogeneous solid water phantom whereas the RPC results utilize an 
anthropomorphic phantom.  These results also agree with previous studies that a 5% dose 
accuracy is achievable and should be the minimum accuracy an institution aims to meet.  In 
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conclusion, although TG-119 is not a true end-to-end test set, it is an easy way to evaluate the 
combined dosimetric effects of several important treatment planning uncertainties. 
1.5 Patient-Specific Quality Assurance 
1.5.1 Phantom-based QA 
Linear accelerators are complicated devices comprised of many moving parts.  It follows 
that there will be some non-zero delivery error when delivering a treatment plan.  The purpose 
of patient-specific QA is to verify that radiation is being correctly delivered for each specific 
patient’s treatment plan.  Patient-specific QA is conventionally carried out using phantom-
based systems.  The phantom-based systems utilized herein are Sun Nuclear’s MapCHECK and 
ArcCHECK systems, shown in Fig. 5 and Fig. 6.  MapCHECK is a planar device that contains 
a planar array of diodes.  A diode is a small (0.019mm3) device for measuring dose.   The 
ArcCHECK phantom is a cylinder made of nearly tissue-equivalent material.  Inside of the 
cylinder are 1386 diodes arranged helically throughout the cylinder.  Whereas MapCHECK2 is 
used to QA radiation fields without gantry rotation, the ArcCHECK is utilized for fields where 
gantry rotation is present.  These QAs are carried out as follows.  First, dose is calculated on 
the phantom geometry.  Next, the treatment plan is physically delivered onto the phantom.  Dose 
is measured using the diodes and compared to that of calculation to make sure the treatment 
plan can be accurately delivered by the linac.  MapCHECK2 and ArcCHECK QAs both utilize 
gamma analysis to determine whether the QA is deemed passing or failing.  The equations 
underlying gamma analysis, shown in Eq.9 and Eq. 10, were developed by Low et al.52 Gamma 
analysis is based on the concepts of dose difference (DD) and distance-to-agreement (DTA), 
where DD is simply the percent difference in dose between calculation and measurement at the 
spot of the diode of interest and DTA is the minimum distance it takes from the diode of interest 
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to reach a voxel in the calculated dose distribution with the case dose as the diode measurement.  
Let r(rm,rc) and γ(rm,rc) be the DTA measurement and DD measurement percent between the 
diode of interest rm and some voxel in the calculated dose distribution rc.   Similarly, let Δd
2
m 
and ΔD2M be the DTA and DD criteria that we are looking to meet.  Common gamma criteria 
are 2%/2mm – 3%/3mm.  A 3%/2mm gamma criteria is utilized by our institution.  Eq. 9 solves 
voxel-wise for Γ, a composite quantity evaluating the combined effects of DD and DTA in 
voxels proximal to the diode of interest.  The per-diode gamma index, γ, is simply the minimum 
value of Γ surrounding the diode.  If γ is less than 1, the measurement result of the diode is 
considered passing.  If γ is greater than 1, the result for that specific diode is considered failing.  
The combined gamma passing rate tells us what percentage of the diodes are passing or failing.  
95-100% is considered passing, 90-95% is passing but warrants investigation, and less than 90% 
is considered failing.  In the case of failure, the QA should be re-done.  If the plan still fails QA, 
the plan should be re-planned.   
𝚪(𝐫𝐦, 𝐫𝐜) =  √
𝒓𝟐(𝐫𝐦,𝐫𝐜)
𝚫𝒅𝒎
𝟐 +
𝛅𝟐(𝐫𝐦,𝐫𝐜)
𝚫𝑫𝑴
𝟐          (9) 
𝛄(𝒓𝒎)  =  𝐦𝐢𝐧{𝚪(𝒓𝒎,  𝒓𝒄)}∀ (𝒓𝒄)                 (10) 
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Figure 5.  SunNuclear’s MapCHECK2 planar diode array. 
 
Figure 6.  Sun Nuclear’s cylindrical ArcCHECK phantom 
 
MapCHECK2, ArcCHECK, and other phantom-based QA methods have been the 
standard of care for years.  However, these measurement-based systems have come under fire 
in recent years.   Several studies have shown diodes to be inaccurate measurement devices.  
Saini et al. shows that diodes typically under-respond on the order of 1-4% for lower 
instantaneous dose rates (~25 cGy/min) as opposed to typical clinical dose rate (> 200 
cGy/min).53   Letourneau et al. shows MapCHECK diodes under-respond by up to 2% at 50 
MU/min compared to 600 MU/min.54 Diode energy dependence has been explored by several 
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studies, albeit to a lesser extent.55-57  Yin et al. shows that unshielded Scanditronix diodes at 
15cm depth can over-respond by as much as 15% to lower energy patient-scattered radiation.  
However, for out-of-field diodes where the radiation spectrum can be significantly softer, one 
should expect an even greater relative over-response by the diodes.  For example, Rickner et al. 
theorizes that diodes will over-respond to 100keV and 500keV photons by a relative 70% and 
30% respectively.58 Comparing ArcCHECK diode measurement in a solid water slab to an ion 
chamber, the ArcCHECK diode was shown to over-respond to radiation by up to 1% 5cm out 
of field.101  Czarnecki et al. showed field size calibration factors to vary by up to 2.0% between 
1x1 cm2 and 10x10 cm2 field sizes.59 However, after applying field size correction factors, 
Chaswal et al. shows diode dose error as a result of field size dependence to be within 0.4% for 
5x5 cm2 to 20x20 cm2 fields.60  The accuracy of the ArcCHECK diodes is assessed as part of 
this study.  
Debate-style manuscripts by Siochi et al. and Smith et al. state that measurement-based 
IMRT is both time-consuming and potentially inaccurate since the measurements are taken in 
a phantom and not the patient’s anatomy.61,62 Furthermore, the reliability of these systems is 
worrisome; 20% of institutions fail RPC’s 7%/4mm gamma criteria despite presenting with 
acceptable gamma pass rates.63 Multiple studies have shown IMRT QA passing rates to be 
weakly correlated with DVH-based metrics.64-66 Given this concern, there has been a general 
movement towards DVH-based QA metrics.  However, when it comes to DVH-based metrics, 
phantom-based systems tend to fall short.  SunNuclear does offer an ArcCHECK-specific 
software package, 3DVH, for reconstructing 3D dose on the patient geometry from 
measurement, however, Tyagi et al. shows that log files are better able to reproduce delivered 
dose on the patient anatomy than this 3DVH software package.67 As part of this study, log file 
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QA on the patient anatomy is compared to AC QA on the ArcCHECK geometry.  The clinical 
relevancy of AC QA passing rates is assessed.  Furthermore, the effectiveness of phantom-
based QA as an anatomical surrogate is assessed. 
1.5.2 Log File QA 
 Log files are records of treatment deliveries stored after each delivery.  These files 
contain a recording of collimator (jaw and MLC), gantry positions, delivered dose rate, 
collimator angle, and MU output as a function of time.  The Elekta log file utilized records log 
files samples at 25Hz (every 40ms).  In addition, the log file contains error values for the 
collimator positions, gantry position, and collimator angle.  Using these log files, a treatment 
plan is reconstructed based on machine parameters from the actual delivery and dose calculated.  
The log file reconstructed dose is then compared to the clinically planned dose.  Log file dose 
can be calculated on either the phantom geometry or patient anatomy.  In the scenario that log 
file dose is calculated on the phantom geometry, log file dose is compared to the clinically 
planned dose using gamma analysis.  However, when calculated on the patient anatomy, log 
file dose can be compared to the clinically planned dose using the same DVH-based metrics 
that were used to optimize the initial treatment plan 
 Log file QA offers multiple significant advantages over conventional phantom-based 
patient-specific QA systems.  Whereas phantom-based systems are time consuming, LF QA is 
a fully automatable software system.  Utilizing phantom-based systems, per-fraction dose 
cannot be tracked.  For example, ArcCHECK is setup before treatment to verify correct plan 
delivery but is not utilized during actual patient treatment.  In comparison, LF QA can be carried 
out during every actual treatment fraction.  By tracking dose to the patient per-fraction, a more 
accurate cumulative dose distribution to the patient can be determined.  In the case of significant 
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dosimetric discrepancy relative to the clinically planned dose, the treatment plan can be adapted.  
In addition, phantom-based systems are largely incapable of root-cause analysis.  Phantom-
based QA is either passing of failing.  For example, if ArcCHECK QA fails, it does not say 
why.  In comparison, LF QA allows for a robust root cause analysis – e.g. was the source of 
error due to MLC error, gantry error, unstable MU output, or some other issue.  Whereas 
phantom-based systems ignore patient-specific anatomical variation, LF QA is capable of 
tracking heterogeneous anatomic dose.  In addition, LF QA provides the potential for online 
treatment tracking and/or real time treatment plan modification.  By tracking the log file in real-
time, dosimetric discrepancy could also be tracked in real time.  If the discrepancy were 
significant enough, the treatment could be halted.  Alternatively, the treatment plan could be 
adapted in real time to instantaneously account for delivery error.  It is noted that the current 
log file system which has been provided to us by Elekta can only be used retrospectively; the 
log file is not acquired in real time. 
  Skepticism with regard to the reliability of measurement-based phantom-based QA has 
led researchers to investigate software-based log file QA as an alternative patient-specific QA 
method.68-74 Using Varian’s dynalog system, Stell et al. showed MU errors were greater for high 
dose rate deliveries.72  Handsfield et al. showed log-file based QA utilizing a secondary Monte 
Carlo dose calculation method is an effective and efficient means of TomoTherapy QA.70   
Kumar et al. shows that log files can carry out IMRT QA with the same accuracy as film.75 Log 
files are also a viable method of VMAT QA for both phantom and patient geometries.67,76  
Defoor et al. shows that log file gamma passing rates as calculated on the patient anatomy 
matched clinical gamma pass rates as calculated on the Delta4 phantom within 1%.76  Tyagi et 
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al. shows that log file dose as calculated on the patient anatomy consistently agreed with the 
planned dose within 2%.67 
The primary concern with the use of log files is that they rely upon a reliable relationship 
between machine read-out and the actual delivery.  For example, in a Varian machine, MLC 
leaf motor counts are converted into leaf position and output to the log file.  As a result, a 
malfunctioning MLC motor, faulty t-nut (connects the motor to the MLC), or loss of encoder 
counts may result in incorrect log file reported MLC positions.  Agnew et al. illustrates this 
exact problem - a loose t-nut resulted in incorrect log file MLC leaf positions.77 However, for 
the Elekta machines at our institution, MLC positional information is determined based upon 
the optically measured position of reflectors on each leaf, thus eliminating the possibility of 
these catastrophic errors assuming that the optical reflectors have been calibrated correctly. At 
our institution, MLC calibration is carried out via monthly picket fence/phantom tests.  These 
tests nominally ensure collimation components are within 1mm of post-calibration baseline 
positions, however they can be somewhat subjective and don’t always directly isolate individual 
leaf position errors.  In addition, calibration can degrade over time.  For these reasons, it may 
be useful to perform Integrity’s Calibration Workflows more often or to implement a more 
objective QA testing.  In addition, log files do not monitor variations in output and beam tuning.  
Thus, these factors must be sufficiently monitor via machine QA.   
A second concern is that LF QA requires an accurate dose calculation method.  Dose 
calculation errors will go unnoticed by LF QA.  It follows that having a robust dose calculation 
method (algorithm + beam model) is of the utmost importance.   In general, dose calculation 
methods have been thoroughly vetted.  For instance, using collapsed-cone CS, Butson et al. 
showed dose calculation can be accurate within 5% of delivered dose for an anthropomorphic 
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lung phantom.78 However, this 5% includes more uncertainties than just dose calculation 
accuracy.  It follows that the accuracy of the CS calculation method is likely in the 2-4% range.  
In a study by Haga et al., MC and CS calculated doses typically agreed within ±2-5% with ion 
chamber measurement in both solid water and cork phantoms.79 Calculations consistently 
agreed within 1.5% of each other in target regions.  These studies show that a dose calculation 
accuracy of 2-3% is achievable.  However, it is the responsibility of each institution to validate 
the accuracy of their beam model(s).  For instance, when it comes to LF QA, it is essential that 
the calculated leaf position precisely matches the actual leaf position to account for subtle 
discrepancies in leaf position as recorded in the log file.  For CS, this is adjusted via the rounded 
leaf tip offset table in Pinnacle’s beam modelling system.80 For MC, SciMoCa utilizes a 
parameter that offsets the leaves from their nominal position as determined using a picket fence 
test.  All MLC positioning systems (log file, Pinnacle, SciMoCa) are nominally accurate to 
0.1mm.  Given the importance of dose calculation accuracy, two dose calculation algorithms as 
well as two forms of LF QA were assessed as part of this study.  The two dose calculation 
algorithms were Pinnacle’s adaptive collapsed-cone convolution-superposition (CS) algorithm 
and a research version of ScientificRT’s SciMoCa Monte Carlo (MC) algorithm.   
The two forms of LF QA analyzed as part of this study were CS-based LF QA (LF-CS 
QA) and MC-based LF QA (LF-MC QA).  In LF-CS QA, the log file reconstructed and planned 
doses both utilize the same CS dose calculation algorithm.  Because the doses utilized the same 
dose calculation method, patient-specific dose calculation accuracy is unknown.  However, for 
LF-MC QA, the log file reconstructed dose instead uses Monte Carlo for dose calculation.  Thus, 
LF-MC QA not only assesses the ability of the machine to accurately deliver the treatment plan, 
but also acts as a secondary dose verification system.  All three terms, LF QA, LF-CS QA, and 
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LF-MC QA will be used during this study.  Where LF QA will be used when referring to log 
file quality assurance as a whole, LF-CS QA and LF-MC QA are more specific terms signifying 
that log file reconstructed dose is being calculated using either CS or MC respectively. 
LF-MC QA also functions as a means of treatment planning QA.  As part of treatment 
planning QA, the dosimetric impact of various beam modelling parameters and machine 
delivery parameters are analyzed.  These include jaw positioning accuracy, MLC positioning 
accuracy, and linear MU output.  The log file monitors each of these factors.  Furthermore, LF 
QA can be used to calculate the dosimetric impact of these factors per-patient on their unique 
anatomy.  It may be the case that current machine QA tolerances for these factors are too lax 
and need tightened, or perhaps the tolerances we have in place are not that necessary.  Log files 
may also present with MLC/gantry errors that are greater than the tolerances set by machine 
QA.  More specifically, machine QA requires MLC positioning to be within ±1% and gantry 
positioning to be within 1°, however, the log file may contain errors greater than these values.  
In this circumstance, the dosimetric impact of these errors ought to be investigated.  If deemed 
significant the cause of this error can then be investigated and potentially corrected for.  As an 
example, perhaps MLC errors greater than what are allowed are occurring when MLC velocities 
are greater than some value.  Or perhaps gantry errors greater than the 1° machine QA tolerance 
are occurring when gantry accelerations exceed some value. MLC velocities and gantry 
acceleration values could then be constrained inside of the treatment planning system so that 
MLC and gantry errors are within tolerance.  It is noted that the effect of MLC and gantry 
rotation on MLC and gantry error are not included in routine machine QA.  By utilizing LF-
MC QA, the effects of beam complexity and patient heterogeneity can also be investigated.  
Previously it was shown that MC and CS can disagree by 3% for IMRT treatments, despite 
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agreeing well for simpler conformal plans.17 This suggests these calculation differences likely 
result from imperfect CS and/or MC beam modeling and/or treatment planning parameters. 
1.6. Chapter Overview 
 The primary purpose of this study was to compare LF QA to ArcCHECK QA (AC QA).  
In this chapter, many of the primary advantages and disadvantages of the two systems were 
investigated.  Chapter 2 is the first of two core chapters in this dissertation.  Herein, diode 
sensitivity dependencies of AC QA diodes were quantified.  In addition, LF QA was compared 
to AC QA when all doses were calculated on the ArcCHECK phantom geometry.  In Chapter 
3, LF-CS QA and LF-MC QA was carried out on the patient’s anatomy, allowing for log file 
reconstructed dose to be directly compared to the clinically planned anatomical dose.  Because 
LF-MC QA is not well established, a protocol for assessing log file reconstructed anatomical 
dose differences was developed.  Using this protocol, anatomically-calculated LF-MC QA 
results were compared to clinical phantom-based AC QA results.  Chapter 4, provides a brief 
overview of the LF QA software that was developed as part of this project.  This software 
includes automation tools for both LF-CS and LF-MC QA.  Finally, in Chapter 5, conclusions 
and the key clinical takeaways of this study are discussed. 
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CHAPTER 2 LF QA FOR TREATMENT PLANNING AND DELIVERY QA: PART 1 
– ARCCHECK GEOMETRY 
2.1 Introduction 
This is largely a comparative study, seeking to determine whether log file QA can 
provide ArcCHECK equivalent accuracy.  First, accuracy of the log file is investigated and the 
Monte Carlo beam model is validated.  Next, the log file dose reconstruction process along with 
strategies for reducing the computational cost of said process was detailed.  Third, the 
dosimetric uncertainty of ArcCHECK QA was re-investigated.  Variation in diode sensitivity 
as a function of dose rate, energy, and field size were investigated.  The effect of these 
parameters on measurement and subsequently ArcCHECK QA results was evaluated.  
Calculated vs. AC-measured dose differences were quantified as functions of diode dose rate 
and energy dependence.  LF and AC QAs were evaluated for experimental plans of varying 
delivery complexity.  Lastly, clinical LF QA and AC QA results were compared.  In this Chapter, 
log file doses are all reconstructed on the ArcCHECK geometry.   
2.2. Methods and Materials 
 For this study, an Elekta Infinity linac equipped with the Agility beam-limiting device 
was utilized.  Plans were selected from previously treated patients that were planned and 
optimized using the Pinnacle3 treatment planning system.  Eleven dual-arc VMAT patients 
were selected for this study (9 H&N, and 2 low dose rate brain).  For the entirety of this thesis, 
all fields were 6MV photon fields. The head and neck cases were selected for their high degree 
of complexity and somewhat lower gamma pass rates.  The two brain cases were selected to 
compare how log file and ArcCHECK QAs respond to low dose rate deliveries.  All 22 arcs 
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were delivered to Sun Nuclear’s ArcCHECK phantom and log files recorded. All beams were 
flattened, 6 MV. 
To compare AC QA to LF QA, five dose distributions were determined for each plan: 
Plan-CS, Plan-MC, LF-CS, LF-MC, and AC.  ‘Plan’ denotes the dose distribution that was 
calculated from the original clinical treatment plan file optimized in Pinnacle, whereas ‘LF’ 
doses were calculated from log files.  CS and MC denote the two dose calculation methods.  
‘AC’ denotes ArcCHECK measurement.  To begin, Plan-CS is recalculated using Monte Carlo 
to get Plan-MC.  Next, each plan was delivered on the ArcCHECK phantom, measurement 
taken, and log files recorded.  For LF-CS dose calculation, in-house code was used to 
reconstruct the log file beams in Pinnacle with a reduced number of log file samples (see Section 
2.2).  For MC dose calculation, the DICOM toolkit (DCMTK) library by OFFIS was utilized 
to convert log files into DICOM RTPLANs containing every log file sample with non-zero MU.  
DCMTK is a collection of open-source C/C++/ANSI libraries and applications implementing 
the DICOM standard.  Whereas LF-MC is calculated using every useful log file sample, LF-
CS is calculated using a reduced number of log file samples.   
2.2.1 Preliminary Validations 
First, the accuracy of our MLC calibration was assessed.  The accuracy of the log file 
records is based on this calibration and thus is of the utmost importance. Elekta’s Log File 
Convertor for Integrity R3.2 records linac delivery parameters (dose rate, gantry/collimator 
angle, leaf/collimator positions, MU) every 40ms.  MU readings are determined via an ion 
chamber in the treatment head of the linac.  Jaw positions are determined electronically via two 
redundant potentiometer voltages.  MLC positions are determined from the video image 
positions of optical reflectors on each MLC leaf.  The accuracy of jaw and leaf positioning, as 
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represented in the log file, hinges on machine calibration and QA.  Jaw and MLC calibration is 
carried out annually as well as after any relevant field service.  Calibration is performed using 
the internal Calibration Workflows contained in the Integrity R3.2 treatment control system 
(TCS), specifically the optical, diaphragm, and leaf workflows.  For monthly QA, picket fence 
patterns are acquired with the iViewGT EPID and a BB array phantom aligned to the crosshairs 
and compared to baseline images acquired just after Calibration Workflows to verify that leaves 
and jaws are within 1mm of their baseline positions.  If any of the collimation components 
appear to be out of tolerance, the appropriate Calibration Workflow is re-run and the appropriate 
picket fence test repeated. 
The ArcCHECK phantom was supported by the iBeam evo H&N extension.  To account 
for this added attenuation, a couch ROI was added to the phantom geometry in Pinnacle beneath 
the ArcCHECK.  In order to create this couch ROI the following process was carried out.  A 
solid water stack was set on top of the H&N extension and a standard farmer chamber was 
inserted into the solid water stack at 10cm depth.  Seventeen 10x10 cm2 fields were delivered 
to the solid water stack at 17 different gantry angles.  These angles were 100° to 260° with 10° 
spacing between them.  Measurement was compared to calculation with this added couch ROI.  
The ROI was optimized to maximum agreement between CS dose calculation and measurement 
for the greatest number of these 17 fields.  
As discussed in Chapter 1, the accuracy of CS and MC is generally well established, 
however, beam modeling accuracy is linac specific and must be thoroughly validated by each 
institution.  Thus, both CS and MC beam models were first thoroughly validated by comparing 
calculated dose to measurement data.  Measurement data for the 6MV Elekta Agility linac was 
acquired using IBA’s Blue Phantom2.  Inline/crossline profiles, PDDs, and output factors were 
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acquired for a variety of field sizes ranging from 1x1 cm2 to 40x40 cm2.  These field sizes are 
displayed in Table 3 in the results section.  Output factors and PDDs and percent depth dose 
data for field sizes less than 5x5cm2 were acquired using a Sun Nuclear EDGE diode.  All other 
measurements were acquired using an IBA CC13 ion chamber (0.13 cm3 volume, 5.8 mm 
length, 3.0 mm radius).  Crossplane profiles were offset half a leaf width (2.5 mm) in the inplane 
direction to minimize the effect of interleaf leakage and to scan close to the center of the Agility 
leaf tips which appear tapered in EPID images.  All profiles were measured at 1.5/5/10/20 cm 
depths.  Ideally, large field profiles should be acquired using a microdiamond or microchamber.  
For the ≥20x20cm profiles taken with a CC13 chamber, substantial penumbral blurring and 
thus poorer agreement between measurement and calculation is expected. The resulting beam 
model was validated by comparing calculated doses to each of the aforementioned 
measurements.  All calculations utilized 1mm dose grid resolution in the direction of 
measurement.  In regard to commissioning and QA of treatment planning dose calculation, 
Smilowitz et al. recommends low-gradient in-field regions match within 1.5%, penumbra agree 
within 3mm DTA, and out-of-field measurements agree within 3% of max dose.81 Therefore, 
the fraction of calculations that meet each of these criteria was determined.  Out-of-field doses 
were also compared using more strict 2% and 1% criteria.  Low-gradient was defined as less 
than 1cGy/mm.  Out-of-field was defined as less than 10% of CAX dose.  Additional per-field 
calculations included percent difference in output factor, mean percent difference in PDD from 
0-35cm, mean percent difference in beam width (50%-50%) over all eight profiles, and mean 
percent difference in penumbral width (80%-20%) over all eight profiles.  Percent PDD 
differences were calculated relative to maximum dose.  Due to insufficient scan length for the 
40x40 field, out-of-field dose and penumbral width was left uncalculated and unanalyzed.   
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2.2.2 Strategies for Reducing the Computational Cost of LF-CS QA 
Log files are reconstructed by converting n number of log file samples into n VMAT 
control points, where a control point is a planning parameter that defines the linac state 
(collimation positions, delivered MU, gantry angle) at some point in the planned treatment 
delivery.  However, Pinnacle places an upper limit of 359 control points on each field, thus 
limiting the number of log file samples that can be reconstructed to 359, despite thousands of 
samples per log file.  In addition to this software limit, utilizing every one of thousands of log 
file samples would result in extremely long CS calculation times.  This is because CS dose 
calculation time scales linearly with the number of control points for the CS method.  There are 
at least a few ways to reduce this cost: (1) utilize CPU and/or GPU parallelization, (2) utilize a 
dose calculation algorithm whose computational cost is independent of the number of control 
points (e.g. Monte Carlo), and/or (3) reduce the number of log file samples reconstructed.  For 
this study, methods 2 and 3 were investigated.  CS dose calculation utilized Oracle’s Sun Server 
X4-2.  MC calculation utilized an Intel i7-3770 and 8GB of RAM. 
The effect of reducing the number of log file samples reconstructed was investigated by 
utilizing 1/2/3/4º control point spacing.  For example, a VMAT arc starting at -179º, ending at 
179º, and reconstructed with a 3º control point spacing would have the following control points: 
-179.xº, -176º, -173º, … 175º, 178º, 179.xº.  Variable x stands for the exact gantry angle at 
which radiation started and stopped delivering radiation according to the log file.  In addition 
to control point spacing, the effect of dose grid resolution (2/3/4 mm) on log file reconstructed 
dose accuracy was analyzed.  Reconstructive effectiveness was quantified by comparing log 
file gamma pass rates (LF-CS vs. AC) with pass rates of the original plan (Plan-CS vs. AC).  
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This metric measures dosimetric improvement due to log files accounting for machine delivery 
errors.  Because LF and AC both account for delivery errors, this metric should be ≥ 0. 
2.2.3 Discrepancy in Calculated vs. Measured Diode Doses 
 The ArcCHECK phantom contains 1386 diodes whose job is to measure the dose 
delivered to the phantom.  However, this measurement can be inaccurate due to various diode 
sensitivity dependencies.  Diode sensitivity dependence is evaluated as a function of dose rate, 
energy, field size, and field complexity.  By quantifying these dependencies the accuracy 
ArcCHECK dose measurement can be better understood. 
2.2.3.1 In-Field Discrepancy: Dose Rate Effect 
Calculated (Plan-CS) vs. measured (MapCHECK2 and ArcCHECK) doses were 
compared for a variety of dose rates (35, 70, 140, 280, and 570 MU/min).  150MU was delivered 
onto the MapCHECK2 diode array for 3x3cm2 and 20x20cm2 field sizes and each dose rate.  
Constant machine output was verified by placing 2cm solid water on top of the MapCHECK 
and inserting an ion chamber at CAX.  In-field and out-of-field dose rate effects were 
investigated; penumbral diodes directly on the field edge were excluded from the analysis.  
MapCHECK2 was initially utilized in order to best isolate dose rate effects; the simpler device 
geometry minimizes any possible spectral effects.  It is important to note that the same diodes 
are used in both MapCHECK2 and ArcCHECK systems.  Systematic effects of dose rate on 
AC QA and LF QA were assessed by delivering a 25x25arc onto the phantom using 70 and 570 
MU/min.   
Dose rate is dynamically determined based upon gantry, jaw, and leaf speed limitations.  
Thus, for deliveries with fixed jaws and leaves, delivered dose rate should be calculable as a 
function of MU, gantry excursion (gantry degrees subtended), and maximum gantry speed 
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(6°/s).  To prove this, 23 10x10 arcs (see Table 1) with varying gantry excursions and MU were 
delivered on the ArcCHECK phantom.  ‘Calculated’ dose rate matched log file data for all cases.  
Next, percent difference in calculated (Plan-CS) and measured diode dose was tracked for each 
of the 23 fields and analyzed as a function of ‘calculated’ dose rate.   
Table 1. 10x10 arcs of varying gantry excursions and MU 
Gantry Start/Stop/Excursion MU 
-90 / -60 / 30 10, 20, 35, 50, 100 
-90 / -30 / 60 20, 40, 70, 100, 200 
-90 / 30 / 120 20, 40, 80, 140, 200, 400 
-90 / 90 / 180 20, 40, 60, 120, 210, 300, 600 
 
2.2.3.2 Out-of-Field Discrepancy: Energy Effect 
 Percent difference in calculated versus measured diode dose was analyzed as a function 
of off-axis distance to determine the effects of off-axis softening on AC QA.  Because off-axis 
spectra vary with field size, static 2x2 cm2, 10x10 cm2 and 25x25 cm2 arcs were assessed.  0% 
and 10% dose thresholds were utilized. 
2.2.3.3. Delivery Complexity 
 The effect of beam segment complexity on calculated vs. measured dose difference was 
investigated for 42 fields delivered onto the ArcCHECK phantom.  100MU static fields were 
delivered at gantry 0° and -90° for 1x7 cm2, 7x1 cm2, 2x8 cm2, 8x2 cm2, 3x5 cm2, 5x3 cm2, 5x1 
0 cm2, 10x5 cm2, 2x2 cm2, 3x3 cm2, 5x5 cm2, 10x10 cm2, 15x15 cm2, and 20x20 cm2 field sizes. 
300MU arcs from -90° to 90° were delivered for the same field sizes.   Two metrics, MPDD 
(mean percent dose difference) and MAPDD (mean absolute percent dose difference), were 
utilized.  These metrics work by comparing any two of the five dose distributions described in 
Section 2.2 at each of 1386 ArcCHECK diode positions.  Equation 1 shows how to calculate 
MAPDD for LF-MC vs. AC  where i is the i-th diode (i = 1-1386) such that ACi is greater than 
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some threshold percentage of max(AC).   MPDD is simply MAPDD without taking the absolute 
value. 
𝑴𝑨𝑷𝑫𝑫 =  𝑴𝒆𝒂𝒏 (|
𝑳𝑭𝑴𝑪𝒊−𝑨𝑪𝒊
𝑨𝑪𝒊
∗ 𝟏𝟎𝟎|)    (11) 
 LF QA and AC QA should agree with one another even for complex fields.  To verify 
this is the case, we divided a 12x12 cm2 static field and 12x12 cm2 arc into 1/4/9/16/36 sub-
fields (i.e. 1 12x12 cm2, 4 6x6 cm2, 9 4x4 cm2, 16 3x3 cm2, and 36 2x2 cm2 fields/arcs).  Each 
static field was setup at gantry 0.  Arcs were a full 358° CW or CCW.  Plans were generated in 
Pinnacle on a ‘prescription’ geometry and then re-calculated and delivered on the ArcCHECK 
geometry.  The prescription geometry, shown in Fig. 7, consisted of three structures.  A 
20x20x20 solid water cube centered on the isocenter serves as the patient volume.  A 10x10x10 
‘Target’ ROI centered on isocenter was utilized for DVH matching purposes; all static fields 
and arcs had matching DVHs.  Lastly, an isocenter-centered 10x10x1 (1cm perpendicular to 
gantry 0° CAX) ‘Prescription’ ROI was created.  Sub-field beam weights were optimized to 
achieve a flat beam profile at 10cm depth for the full field; dose was optimized to the 
Prescription ROI using a 1Gy minimum DVH objective and 1.1Gy maximum DVH objective 
of equal priority.  Static field beam weights were copied to their corresponding arc fields.  Each 
set of sub-fields was delivered onto the ArcCHECK phantom.  Sub-field measurements were 
combined such that ten combined-field measurements (5 static field and 5 arc) were created.  
Differences in AC, Plan-CS, Plan-MC, and LF-MC doses were assessed as a function of the 
size and number of segments delivered.   
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Figure 7. (left) The ‘prescription’ geometry.  The teal isodose line displays the flatness of the combined 
12x12 field when (right) 36 abutting 2x2 fields are delivered 
 
2.2.4 Comparing LF QA & AC QA 
 Plan, LF, and AC dose distributions are subject to varying sources of dose uncertainty 
and share various correlated factors.  AC QA compares ‘Plan’ and AC doses; discrepancies 
stem from phantom-dependent inaccuracies (e.g. setup error, diode miscalibration/drift, diode 
sensitivity dependencies, and physical diode limitations), dose calculation inaccuracy, delivery 
error, and variation in beam consistency (drift in beam output/symmetry).  LF and AC doses 
both account for delivery error.  It follows that LF and AC doses should agree better than Plan 
and AC doses.  For LF QA, LF and Plan doses are compared.  Conventionally this means 
comparing LF-CS to Plan-CS to isolate delivery error.  However, dose calculation accuracy 
should also be verified.  By comparing LF-MC to Plan-CS, both delivery error and dose 
calculation accuracy are investigated.  It is important to note that whereas AC accounts for 
variations in beam consistency, neither LF nor Plan doses do.  This means that LF QA ignores 
variation in beam output. 
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AC and LF QAs were carried out for 11 clinical dual-arc VMAT patients (9 H&N, 2 
low dose rate brain).  Dose was determined at each of ArcCHECK’s 1386 diode locations for 
each arc and each of the five aforementioned dose distributions.  Various pairs of these five 
plans were compared.  Plan pair comparisons included (1) Plan-CS vs. AC, (2) Plan-MC vs. 
AC, (3) LF-CS vs. AC, (4) LF-MC vs. AC, (5) Plan-MC vs. Plan-CS, (6) LF-CS vs. Plan-CS, 
(7) LF-MC vs. Plan-MC, and (8) LF-MC vs. Plan-CS.   Three comparisons metrics were utilized.  
First, 2%/2mm and 1%/1mm global gamma pass rates were calculated using 10% (conventional) 
and 85% (in-field/target approximation) dose thresholds.  Second, global percent dose 
difference was calculated at each diode position and averaged over all diodes (1386 diodes/arcs 
* 22 arcs).  ‘Global’ indicates that percent differences have been scaled relative to the maximum 
dose value being compared to, e.g. for X vs. Y where X and Y are two 1386 element dose 
matrices.  Global percent diode dose difference (GPDDD) is calculated according to Eq. 12.  
This second metric was calculated in order to isolate and quantify systematic and statistical 
dose uncertainties due to delivery error, dose calculation difference, and the ArcCHECK 
phantom (e.g. diode sensitivity dependencies) as well as to confirm the gamma analysis results.  
The dosimetric comparisons studies as well as their significances are displayed in Table 2. 
                                            𝑮𝑷𝑫𝑫𝑫 =  𝒎𝒆𝒂𝒏 (
𝑿−𝒀
𝐦𝐚𝐱 (𝒀)
∗ 𝟏𝟎𝟎)    (12)         
 
Table 2. Dosimetric comparisons along with their significance.  When two comparisons are listed it is 
because those two comparisons are being compared. 
# Comparison 1 Comparison 2 Significance 
1 Plan-CS vs. AC Plan-MC vs. AC Which dose calculation method 
matches AC better? 
2 Plan-MC vs. Plan-CS -- Dose difference due to calculation 
method is isolated. 
3 LF-CS vs. AC Plan-CS vs. AC Log files should match AC better.  
Is this the case?  4 LF-MC vs. AC Plan-MC vs. AC 
5 LF-MC vs. Plan-MC -- Machine delivery error is isolated. 
6 LF-CS vs. Plan-CS -- 
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7 LF-MC vs. Plan-CS Plan-CS vs. AC 
Plan-MC vs. AC 
How do LF QA and AC QA 
compare? 
  
2.3 Results and Discussion 
2.3.1 Preliminary Validations 
 For the Elekta Infinity/Agility linac used in this study, Calibration Workflows 
resulted in leaf, leaf bank, and jaw positions agreeing with nominal positions within 
approximately 0.3mm each (0.1mm RMS).  Despite the initial accuracy of these calibration 
processes, agreement with nominal positions can degrade over time.  Monthly picket 
fence/phantom tests nominally ensure collimation components are within 1mm of post-
calibration baseline positions, however they can be somewhat subjective and don’t always 
directly isolate individual leaf position errors.  For these reasons, it may be useful to perform 
Calibration Workflows more often if utilizing LF QA clinically, or to implement more objective 
collimator component QA testing.  The necessary increased frequency of calibration or 
exploration of other QA methods were not investigated as part of this study. 
The ArcCHECK phantom is supported by a H&N extension.  A couch ROI was added 
to the phantom geometry in Pinnacle to account for this added attenuation.  Calculation was 
compare to measurement for 17 10x10 cm2 fields delivered at 17 different gantry angles passing 
through the H&N extension.  With the added H&N ROI calculation agreed with measurement 
within 0.25% for all seventeen fields.  On average, calculation agreed with measurement within 
0.10% for these fields. 
Verification data comparing MC calculation to measurement is shown in Table 3.  The 
SciMoCa model utilized herein met each of the aforementioned AAPM recommended criteria 
100% of the time.  Furthermore, 96.5% of out-of-field measurement data matched calculation 
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within 2%.  For field sizes ≤ 20x20 cm2, 97% of out-of-field measurement data matched 
calculation with 1%.  For the larger 30x30 cm2 field size, 44% of measurement data matched 
within 1%.  On average, over all field sizes, calculated output factors deviated from 
measurement by 0.20 ± 0.17% and PDDs agreed within 0.65±0.19%.  On average, beam width 
varied by 0.54 ± 0.38%.  On average, over all field sizes, and all profiles (both in-plane and 
cross-plane at each depth), penumbral width varied by 1.1 ± 0.5% of the field size.  The absolute 
differences in penumbral width are shown per-field in Table 3.  These values are shown in 
parentheses.  For field sizes less than or equal to 10x10cm this difference was within 0.5mm, 
however penumbral width varied by almost 3mm for the 30x30 cm2 field; these absolute 
differences are displayed in parentheses in Table 3.    As hypothesized, deviation in penumbral 
width was larger for the profiles taken with the CC13 chamber (20x20 cm2 and 30x30 cm2) 
than the EDGE diode (< 20x20 cm2).  This larger deviation is expected to result from penumbral 
blurring and not poor beam modeling.   
Table 3. 6MV Elekta Agility Monte Carlo beam model validation results are shown.  Absolute percent 
differences in output factor (OF), percent depth dose (PDD), penumbral width (PW), and beam width 
(BW) are shown for each field size.  Due to insufficient measured profile length, differences in 40x40cm 
penumbra were not calculated.   
Field (cm) OF |%Diff| PDD Mean(|%diff|) PW Mean(|%diff|) BW Mean(|%diff|) 
1x1 0.3% -- -- -- 
2x2 0.4% 0.64 ± 0.23% 1.9 ± 1.0% (0.4mm) 0.9 ± 0.5% (0.2mm) 
3x3 0.5% 0.95 ± 0.20% 1.5 ± 1.1% (0.4mm) 1.0 ± 0.5% (0.3mm) 
4x4 0.0% -- -- -- 
5x5 0.3% 0.22 ± 0.12% 1.0 ± 0.3% (0.50mm) 0.8 ± 0.5% (0.4mm) 
6x6 0.4% -- -- -- 
8x8 0.3% -- -- -- 
10x10 0.0% 0.51 ± 0.11% 0.5 ± 0.3% (0.50 mm) 0.6 ± 0.3% (0.6mm) 
12x12 0.3% -- -- -- 
15x15 0.1% 0.61 ± 0.11% -- -- 
20x20 0.0% 0.75 ± 0.10% 0.7 ± 0.4% (1.5 mm) 0.1 ± 0.1% (0.2mm) 
25x25 0.2% 0.75 ± 0.12% -- -- 
30x30 0.1% 0.72 ± 0.17% 1.0 ± 0.3% (2.9mm) 0.14 ± 0.11% (0.4mm) 
35x35 0.1% 0.73 ± 0.17% -- -- 
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40x40 0.0% 0.64 ± 0.25% -- 0.25 ± 0.11% (1.0mm) 
All 
Combined: 
0.20 ± 0.17% 0.65 ± 0.19% 1.1 ± 0.5% 0.54 ± 0.38% 
 
2.3.2 Strategies for Reducing the Computational Cost of LF-CS QA 
Fig. 8 displays change in pass rate ((LF-CS vs. AC) minus (Plan-CS vs. AC)) as a 
function of control point spacing and dose grid resolution for 10 (8 H&N, 2 Brain) of the 22 
clinical VMAT arcs used in this study.  To make the plot clearer, error bars were plotted only 
in one direction for each curve.  For the dose grid resolution curve, 2° control point spacing is 
utilized.  2mm resolution offers a 1.2±0.5% increase in pass rate compared to 3mm.  For all 
subsequent studies, a 2mm dose grid resolution was utilized.  Increased control point spacing 
resulted in lower LF-CS pass rates.  Yielding a negative change in pass rate, control point 
spacing ≥ 2° was deemed unacceptable.  1° LF-CS spacing was used throughout the rest of this 
study.  Similarly, Barbeiro et al. found log files reconstructed with ~3 times as many control 
points as the TPS agreed better with film than those reconstructed with the TPS’ 
discretization.82 
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Figure 8. Difference in 2%/2mm pass rate ((LF-CS vs. AC) minus (Plan-CS vs. AC)) is plotted as a function 
of varying dose grid resolution (fixed 2° control point spacing) and control point spacing (fixed 2mm dose 
grid resolution).  For visualization purposes, error bars (1σ) are plotted only in one direction. 
 
Computational cost for CS was typically 12 seconds per control point.  This corresponds 
to 18 minutes for a 358° arc planned with 4° control point spacing or 72 minutes for a log file 
plan reconstructed using 1° control point spacing.  In comparison, MC dose calculation took ~5 
minutes to calculate log file dose using every control point.  This discrepancy in computational 
cost stems primarily from CS’s computational cost being dependent on the number of control 
points, but also from the aforementioned differences in hardware.   
2.3.3 Discrepancy in Calculated vs. Measured Diode Dose 
2.3.3.1 In-Field Discrepancy: Dose Rate Effect 
Fig. 9 plots in-field reduction in diode measurement with decreasing dose rate with 
respect to 570 MU/min for 3x3cm and 20x20cm MapCHECK2 fields, a 25x25cm ArcCHECK 
field, and the 23 10x10cm ArcCHECK fields in Table 1.  For the MapCHECK2 measurements, 
low dose rate (35 MU/min) measurements were -1.2±0.4% and -1.6±0.4% lower than the high 
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dose rate (570 MU/min) measurements for 3x3cm and 20x20cm fields respectively.  The trend 
shown in Fig. 9 is similar to Letourneau et al’s, although slightly less in magnitude; Letourneau 
measured an under-response of -2.0% at 50MU/min.54 Variance in dose rate effect with field 
size is believed to result from the reduced signal observed with smaller field sizes.  Jursinic’s 
‘hypothesized reaction scheme’ would suggest smaller signals are less susceptible to the dose 
rate effect.83 Eq. 13 quantifies the ratio of diode sensitivity when traps are open to that when 
traps are closed.  The terms τd, τRG1, and τtrap1 are the charge lifetimes for the detection circuit, 
recombination-generation (R-G) centers, and traps respectively.  Charge lifetime is the average 
time it takes for charge to enter and exit a system.  Traps are locations in a solid that restricts 
the movement of charge.  These traps results as a function of chemical impurities or irregular 
atomic spacings. R-G centers result from atomic impurities in semiconductors that introduce 
additional allowed electron levels in the band gap, slowing charge collection in the 
semiconductor diode.  This would also explain why out-of-field diodes registered identical 
doses for low and high dose rates.  Delivering a static 25x25cm arc so that all diodes were in-
field, ArcCHECK measurement behaved similarly to MapCHECK2; measurement decreased 
with decreasing dose rate.  Lastly, delivered dose rate was calculated from MU and gantry 
excursion for the 23 10x10cm arcs shown in Table 1.  This ‘calculated’ dose rate matched the 
actual log file determined dose rate for all cases.  Subsequently, as displayed by the solid line 
in Fig. 9, variation in in-field diode measurement as a function of dose rate agreed well with 
previous results. 
𝑺𝒕𝒓𝒂𝒑𝒔 𝒐𝒑𝒆𝒏
𝑺𝒕𝒓𝒂𝒑𝒔 𝒄𝒍𝒐𝒔𝒆𝒅
∝ √
𝟏
𝛕𝒅
+
𝟏
𝝉𝑹𝑮𝟏
𝟏
𝝉𝒅
+
𝟏
𝝉𝑹𝑮𝟏
+
𝟏
𝝉𝒕𝒓𝒂𝒑𝟏
     (13) 
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Figure 9. Reduction in in-field diode measurement with decreasing delivered dose rate is plotted for (1) 3x3 
and 20x20cm MapCHECK2 fields, (2) a 25x25 ArcCHECK arc, and (3) 23 10x10 arcs.  Reduction is 
normalized to 570 MU/min. 
 
 To better understand the clinical effect of dose rate dependence on AC QA, MC and CS 
calculated doses were compared to AC measurement for each diode in an open 25x25cm arc 
for both 70 and 570 MU/min dose rates.  Plan-CS vs. AC percent dose differences were -2.1 ± 
0.5% and -0.7 ± 0.5% at 570 and 70MU/min dose rates respectively.  In comparison, Plan-MC 
vs. AC percent dose differences were 0.3 ± 0.8% and 1.7 ± 0.8%.  Interestingly, because MC 
doses were generally higher than CS doses and higher dose rates resulted in greater 
measurement, MC dose differences were smaller for high dose rates, while CS dose differences 
were smaller for low dose rates.  In comparison to AC QA, LF QA should be invariant with 
respect to dose rate.  To verify whether this is indeed the case, percent difference in 70MU/min 
vs. 570MU/min LF-MC dose was calculated for the same 25x25cm arc; per-diode dose 
difference was 0 ± 0.85% and 0 ± 0.21% when calculated with 1% and 0.25% MC dose 
uncertainties, respectively.  This shows that whereas AC QA is sensitive to dose rate and could 
yield false positives/negatives, LF QA does not have this issue. 
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Table 4. 10x10 arcs of varying gantry excursions and MU 
Gantry Start/Stop/Excursion MU 
-90 / -60 / 30 10, 20, 35, 50, 100 
-90 / -30 / 60 20, 40, 70, 100, 200 
-90 / 30 / 120 20, 40, 80, 140, 200, 400 
-90 / 90 / 180 20, 40, 60, 120, 210, 300, 600 
 
2.3.3.2 Out-of-Field Discrepancy: Energy Effect 
 Fig. 10 displays percent difference in calculated (Plan-CS and LF-MC) versus AC 
measured diode dose as a function of off-axis distance for a 10x10cm 358° arc.  For the in-field 
region, measurement and calculation agreed well.  In the penumbral region, significant dose 
difference is seen.  Penumbral differences are attributed to imperfect geometry (e.g. imperfect 
linac isocentricity, imperfect leaf calibration, and setup error) and physical diode limitations 
(e.g. finite size), as well as the two issues discussed in the next paragraph.  
Out-of-field, calculation is much lower than measurement.  This disagreement is 
comprised of two major components.  First, the calculation model could be underestimating 
collimator scatter and head leakage at greater off axis distances.  For CS, this is typical of many 
institutions and is known to be the case at our institution as well.84-88 Second, diodes could be 
over-responding to the low energy patient-scattered photons.  Rickner et. al theorizes 30% and 
70% increases in diode sensitivity to 0.5MeV and 0.1MeV photons.58 The typical energy range 
of patient-scattered photons is right in this range.89 Thus, one can expect an approximate 50% 
over-response to low energy photons, and an approximate 30% net over-response after 
multiplying by the low energy component of the fluence.  Figure 10 illustrates the percent 
difference in calculated dose (Plan-CS and LF-MC) and the ArcCHECK measured dose as a 
function of off-axis distance for a 10x10 cm2 358° arc. The MC results of are in good agreement 
with Rickner et al.; a relative 10-30% over-response by out-of-field diodes is concluded for this 
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10x10 cm2 field.  It is important to note this is for a 0% dose threshold.  A 10% dose threshold 
is explored below to determine clinically relevant effects only. 
  
Figure 10. Calculated vs. measured dose differences are plotted as a function of axial distance from 
isocenter for a 10x10 arc using a) Plan-CS and b) LF-MC calculated doses. 
 
 Field size plays a critical role in determining the energy spectrum of photons at each 
diode.  Here, the effect of field size on energy spectrum, and subsequently diode sensitivity was 
studied.  Three static 200MU arcs (2x2 cm2, 10x10 cm2, 25x25 cm2) were delivered on the 
ArcCHECK phantom.  Fig. 11a and Fig. 11c plot histograms of percent difference in calculated 
versus measured diode dose for each field size and for CS and MC respectively.  Fig. 11b and 
Fig. 11d plot the same histograms with a 10% dose threshold applied.  Histograms consisted of 
a tight primary peak and prolonged ‘spectral’ out-of-field distribution for both CS and MC. 
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Figure 11. Histograms of percent diode dose difference (calculated vs. measured) for CS and MC with 
respect to ArcCHECK measurement.  The left plots (a, c) utilize no threshold, while the right plots (b, d) 
utilize a 10% threshold based off the maximum measured dose. 
 
As discussed previously, this ‘spectral’ distribution results from inaccurately calculated 
collimator and head leakage as well as diode over-response to patient-scattered radiation.  Dose 
differences increased with decreasing field size.  By shrinking the field, the distance from the 
field edge to distal diodes increases.  This results in more medium to scatter off and thus a softer 
photon spectrum and greater diode over-response.  As illustrated by the relative positions of 
their out-of-field distributions as well as the integral area of these distributions, MC yielded 
better agreement with out-of-field measurement than CS.  For the 2x2 cm2 field size, a good 
portion of CS’s spectral distribution is centered around -90%.  This corresponds to a 10 times 
greater measured versus calculated dose.  This massive difference is in part due to an 
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underestimation of out-of-field dose by the CS method, but also largely due to the extremely 
low dose – a low absolute dose will yield a larger relative dose difference.  For the 2x2cm MC 
field, measurement is 70% higher than calculation.  Given the diode over-response values 
mentioned in 3.3.2, 70% over-response is reasonable.  It is important to note that some portion 
of this discrepancy will be due to calculation inadequacies. 
  Despite the very large discrepancies seen in Fig. 11a/c, when a standard 10% dose 
threshold is applied (Fig. 11b/d), much of this out-of-field component is eliminated.  For 
instance, for the 2x2cm field where the absolute quantity of patient scatter is minimal, there is 
a miniscule out-of-field distribution.  Thus, diode energy dependence is going to result in very 
few failing diodes.  However, for the 10x10cm field where the absolute magnitude of patient 
scatter is greater, the number of failing out-of-field diodes that are above the measurement 
threshold is more noticeable - energy effects are seen on the order of 3-5% of the maximum 
measured dose.  Although systematic uncertainties due to energy and dose rate will cancel out 
to some degree, when compared to standard 2-3% gamma criteria, 3-5% over-response to lower 
energy radiation remains worrisome.  
2.3.3.3 Delivery Complexity  
 Static fields/arcs with a wide variety of field sizes were delivered onto the ArcCHECK 
phantom and log files reconstructed using Monte Carlo.  LF-MC calculated dose is compared 
to AC diode measurement using MPDD and MAPDD along with an 85% dose threshold.  Fig. 
12a and 12b display MPDD and MAPDD respectively as a function of field size (FSX · FSY).  
Smaller fields yielded greater MAPDD values, indicating greater LF-MC vs. AC disagreement 
for smaller field sizes.  Negative and positive MPDD values were seen because an 85% dose 
threshold will include some field penumbra.    Consequently, any small shift in diode position 
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due to setup error or MLC position due to leaf calibration error can result in large differences 
between calculation and measurement.  Depending on the position of the diode with respect to 
CAX (e.g. ±x̂/ŷ), direction of setup error, and direction of leaf calibration error, measured diode 
dose may increase or decrease with respect to calculation.   
 
Figure 12. LF-MC and AC doses are compared for varying field sizes using an 85% dose threshold.  a) 
Mean Percent Dose Difference (MPDD) and b) Mean Absolute Percent Dose Difference (MAPDD) are 
plotted against FSx*FSy for all the aforementioned fields in Section 2.2.3. 
 
 Delivering various combinations of abutting fields onto the ArcCHECK phantom, 
calculated (LF-MC, Plan-MC, Plan-CS) vs. AC measured dose difference was evaluated as a 
function of segment size and quantity.  Table 5 displays MPDD values for each static and arc 
field arrangement using both 10% and 85% dose thresholds.  As the number of segments 
increased, Plan-CS increasingly deviated from measurement (max 13%).  This Plan-CS dose 
difference likely occurs due to the out-of-field dose mismatch seen between CS and AC in 
section 2.3.3.2.  This discrepancy is seen not only for the 10%, but also the 85% dose threshold.  
This is because what is considered out-of-field for one segment may be considered in-field for 
the combined 12x12cm field.  Plan-MC and LF-MC matched measurement within a few percent 
for all cases.  LF-MC and Plan-MC deviated from measurement by 1.42 ± 1.2% and 1.56 ± 1.2% 
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on average respectively.  This shows improvement by accounting for delivery errors was only 
0.14%. 
Table 5. MPDD (mean percent dose difference w.r.t AC) values are displayed for various field 
complexities, static and arc fields, and for 10% and 85% dose thresholds.   
Field(s) → 12x12cm 4 6x6cm 9 4x4cm 16 3x3cm 36 2x2cm 
Threshold ↓ Static Fields 
LF-MC 10% 1.0 ± 11.0 -0.4 ± 11.1 0.2 ± 10.5 0.4 ± 9.4 4.5 ± 17.4 
 85% -1.1 ± 1.4 -2.7 ± 2.2 -1.2 ± 2.4 -0.8 ± 3.3 1.8 ± 4.8 
Plan-MC 10% 3.4 ± 10.2 2.3 ± 12.2 0.9 ± 9.3 -0.5 ± 8.5 2.3 ± 16.6 
 85% 1.4 ± 1.4 -0.1 ± 1.6 -0.5 ± 1.6 -1.9 ± 3.0 -1.0 ± 3.6 
Plan-CS 10% -0.2 ± 11.6 -2.1 ± 13.6 -3.6 ± 10.7 -6.7 ± 9.2 -11.4 ± 13.5 
 85% -1.5 ± 1.6 -4.3 ± 3.5 -4.6 ± 3.5 -6.9 ± 3.0 -7.6 ± 2.3 
 Arcs 
LF-MC  10% 0.3 ± 6.2 -2.4 ± 6.6 -2.7 ± 8.2 -3.8 ± 10.3 -0.5 ± 21.5 
 85% 0.2 ± 1.3 -1.8 ± 1.6 -0.9 ± 2.0 -0.1 ± 1.9 -1.6 ± 6.2 
Plan-MC 10% 2.7 ± 5.9 -0.2 ± 6.6 -2.1 ± 8.0 -3.7 ± 10.2 -0.7 ± 21.6 
 85% 2.8 ± 1.3 0.6 ± 1.6 -0.1 ± 1.9 -0.3 ± 1.9 -3.6 ± 3.2 
Plan-CS 10% -0.2 ± 11.6 -2.1 ± 13.6 -3.6 ± 10.6 -6.6 ± 9.2 -13.0 ± 24.8 
 85% -1.4 ± 1.6 -4.2 ± 3.5 -4.6 ± 1.9 -6.9 ± 3.0 -11.7 ± 2.9 
 
2.3.4 Comparing LF QA & AC QA 
Gamma pass rates were calculated for each of 22 clinical beams and each dose-pair 
shown in Table 6 using a 10% dose threshold.  Comparing #3 to #1, we saw lower LF-CS than 
Plan-CS pass rates, suggesting even 1° control point spacing was insufficient.  Comparing #4 
to #2, reconstructive accuracy was evaluated for the full 25Hz log file; pass rates were identical 
or improved for 17/18 (2%/2mm) and 14/18 arcs (1%/1mm).  High pass rates for #5 and #6 
indicate both dose calculation differences and machine delivery errors were small.   LF QA 
results (#7) were similar to AC QA results (#1/2).   
Table 6. 2%/2mm and 1%/1mm gamma pass rates are shown for each dose-pair.   
# Comparison 2%/2mm 1%/1mm 
1 Plan-CS vs. AC 97.5 ± 1.6% 81.6 ± 6.5% 
2 Plan-MC vs. AC 96.5 ± 4.2% 78.1 ± 9.9% 
3 LF-CS vs. AC  97.0 ± 2.4% 79.2 ± 8.1% 
4 LF-MC vs. AC 97.3 ± 3.2% 78.9 ± 10.3% 
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5 Plan-MC vs. Plan-CS 99.0 ± 2.4% 85.0 ± 8.2% 
6 LF-MC vs. Plan-MC 99.6 ± 0.4% 91.0 ± 2.7% 
7 LF-MC vs. Plan-CS 96.8 ± 5.1% 76.3 ± 11.6% 
 
Values are calculated for the same 22 beams for each plan pair in Table 7  Comparison 
#5 isolates differences in dose calculation method; MC and CS agreed within 1-2%.  
Comparisons #6/7 isolate delivery errors for CS and MC respectively; the effect of delivery 
error was ~0±1%.  Comparing #3 to #1 and #4 to #2, the effects of delivery error are again seen 
to be very small for this Agility system.  #2/4/5 show MC dose was systematically 1.2% higher 
than CS dose when utilizing an 85% dose threshold.  This is believed to result from slight MC 
vs. CS beam model differences stemming from how CS dose is normalized to a 10x10cm field 
at 10cm depth and MC is not.  Rather, the MC beam model was simply designed to best match 
calculation to measurement for the greatest amount of PDDs and dose profiles.  Accounting for 
both delivery error and calculation difference, comparison #8 is this study’s standard LF QA 
comparison.  Summing systematic differences linearly and statistical differences in quadrature, 
#8 equals #5 plus #7 for both dose thresholds.  Eliminating phantom error sources resulted in 
substantially reduced uncertainty; values for #5-8 were ~0.8 ± 1.2% lower than #1-4.  We 
conclude phantom-based uncertainty is ~0.8 ± 1.2%.  It is important to note that phantom-
dependent uncertainty includes not only measurement and setup uncertainties, but also any 
potential beam inconsistencies due to imperfect machine QA that the log file does not track.  
Gamma and statistical analyses both led to the same conclusions. 
Table 7. Global percent diode dose differences (mean ± σ) are displayed for various plan pair comparisons 
and for both 10% (standard) and 85% (target) dose thresholds.   
 Comparison 10% Threshold 85% Threshold 
#1 Plan-CS vs. AC 0.8 ± 1.8% 0.8 ± 2.6% 
#2 Plan-MC vs. AC 1.0 ± 1.8% 2.1 ± 2.5% 
#3 LF-CS vs. AC 1.0 ± 1.8% 0.8 ± 2.6% 
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#4 LF-MC vs. AC 1.0 ± 1.7% 2.1 ± 2.5% 
#5 Plan-MC vs. Plan-CS 0.2 ± 1.1% 1.2 ± 1.7% 
#6 LF-CS vs. Plan-CS 0.2 ± 1.0% 0.4 ± 1.4% 
#7 LF-MC vs. Plan-MC 0.1 ± 0.9% 0.0 ± 1.3% 
#8 LF-MC vs. Plan-CS 0.2 ± 1.3% 1.2 ± 2.1% 
 
2.4 Summary 
As discussed briefly in the introduction, there exist distinct advantages and 
disadvantages of the two QA systems.  The key advantage of ArcCHECK is that it directly 
measures dose; physicists can trust measurement within the ranges of uncertainty set forth in 
this study. However, it is difficult to determine the cause of failing pre-treatment QA.  In 
comparison to AC QA, LF QA is unaffected by phantom-dependent uncertainties and capable 
of isolating the cause of dose difference.  The downside of LF QA is that it relies heavily on 
machine QA and accurate dose calculation.  Log file reconstructed dose would be more accurate 
if beam limiting device (BLD) calibration was carried out more often.  Reconstruction accuracy 
could be further improved by better maintaining beam output and symmetry whether through 
more frequent QA or tighter tolerances.  Furthermore, LF QA is unable to account for dose 
calculation differences when utilizing the same dose calculation method as the TPS.  Thus, LF 
QA should ideally utilize an independent dose calculation method that has been thoroughly 
vetted as detailed in TG-106.90 In the case of dose deviance between the two methods, 
ArcCHECK can be utilized as a second check.  Assuming a non-MC TPS dose calculation 
engine, Monte Carlo is well suited for LF QA.  Conventionally, MC is deemed accurate, but 
slow.  However, reconstructing every log file sample with no increase in cost, LF-MC QA is 
not only accurate, but exceptionally fast.  Once properly setup, LF-MC QA is a fully 
automatable patient-specific QA technique that can quickly and accurately calculate per-
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fraction delivered dose.  However, given the increased reliance on machine QA and dose 
calculation accuracy, LF QA should at least initially be used only as a supplement to current 
QA systems.   
2.5 Conclusion 
In Chapter 2, LF QA is assessed as a potential supplement or potential replacement of 
ArcCHECK QA.  First, preliminary validations were carried out to assure there are no flaws in 
the work that we are carrying out here.  The beam models and MLC calibration were both 
verified to be accurate.  For LF-CS QA, varying control point spacings were investigated in 
order to determine the optimal number of log file samples that should be utilized.  Utilizing 
control point spacing greater than 1° resulted in substantially degraded dosimetric accuracy.  
LF-CS QA utilizing 1° control point spacing and LF-MC QA utilizing the full 25Hz log file 
both yielded equivalent results to AC QA.  Next, the ability of diodes to accurately measure 
dose was investigated.  Calculation and ArcCHECK measurement differed by up to 1.5% in-
field due to variation in dose rate and up to 5% out-of-field.  For highly segmented experimental 
plans, despite CS calculation deviating by as much as 13% from AC measurement, Plan-MC 
and LF-MC doses generally matched AC measurement within 3% (mean 1.56% and 1.42% 
respectively).  Finally LF-CS QA and LF-MC QA as carried out on the phantom geometry was 
carried out and compared to conventional AC QA.  Carrying out AC QA and LF QA for 22 
clinical VMAT arcs, phantom-dependent, calculation method-dependent, and delivery error-
dependent dose uncertainties were found to be 0.8 ± 1.2%, 0.2 ± 1.1%, and 0.1 ± 0.9% 
respectively.  It follows that by eliminating phantom-dependent uncertainty, LF QA is 
theoretically more accurate than AC QA.  However, none of the doses utilized (AC, MC, CS) 
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can truly be considered a gold standard.  Without a gold standard, we merely conclude that LF 
QA and AC QA offer similar dosimetric accuracy.  
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CHAPTER 3 LF QA FOR TREATMENT PLANNING AND DELIVERY QA: PART 2 
– PATIENT ANATOMY 
3.1. Introduction 
In the previous chapter, log file doses were reconstructed on the ArcCHECK geometry. 
Ultimately, LF-MC QA and LF-CS QA were deemed to be equivalent to ArcCHECK QA given 
standard TG-40 and TG-142 machine QA protocols are carried out.  In this chapter, LF QA is 
instead carried out on the patient specific anatomy.  DVH-based metrics as well as the 
aforementioned TCP formulation are used to evaluate the differences between the calculated 
treatment planning dose and the dose reconstructed using LF-MC QA.  In addition, LF-MC QA 
is utilized as a treatment planning QA tool. 
There are three key objectives of this study: (1) to establish the accuracy of LF-MC QA, (2) 
to compare the performance of patient-specific LF-MC QA with phantom-based QA, and (3) 
to quantify the causes of discrepancy determined by LF-MC QA.  To achieve objective 1, the 
accuracy of MC dose calculation is assessed versus commissioning data as well as phantom 
measurement setups.  To fulfill objective 2, LF-MC QA results on the patient anatomy are 
compared to clinical ArcCHECK results.  For objective 3, dose discrepancy is broken down 
into delivery error, gantry discretization difference, and dose calculation difference.  Dosimetric 
discrepancy due to calculation method was further broken down as a function of beam 
complexity and patient heterogeneity.  Although LF-MC QA on the patient anatomy is the main 
focus of this study, Monte Carlo may not be available for every institution.  Thus, delivery error 
was also assessed using LF-CS QA. 
3.2. Materials & Methods 
3.2.1. Dose Calculation Validation 
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Both dose calculation methods were first thoroughly validated with respect to measurement.  
Calculation was first investigated for square fields as delivered on a the homogeneous IBA 
Blue Phantom water tank.  It is mandatory that calculation methods agree with measurement 
well for these simple square fields in a homogeneous medium.  If they don’t agree well for 
square fields and a homogeneous geometry then they will not agree well for more 
complicated plans delivered on heterogeneous patient anatomy.  Next, more complicated 
clinical fields were delivered onto a homogeneous solid water stack.  Measurement was 
compared to calculation to assure that we are able to accurately deliver complicated fields.  
However, neither of these tests assess the ability of CS and MC to accurately calculate dose in 
a heterogeneous environment, thus CS and MC calculation was also compared to 
measurement in a heterogeneous cork phantom for square fields. 
3.2.1.1. Water Tank Measurement Data – Square Fields 
It is important to note that the MC beam model was redone using a newer set of 
measurement data (M2) since Chapter 2.  Thus, for this paper, CS and MC are commissioned 
using two different, but similar, sets of measurement data – M1 and M2 respectively.  To 
investigate the quality of the beam models the following comparisons were made.  CS and MC 
were compared to M1 and M2 respectively.  M2 was compared to M1 to make sure the 
measurements were accurate within approximately 1%.  Lastly, MC and CS were compared.  
M2 was acquired in the same way as M1 except for two key differences.  First, output 
factors less than 5x5cm2 and PDDs less than 2x2cm2 were acquired using a PTW60019 
microDiamond.  Second, M1 was affected by a software bug that M2 was not affected by.  This 
bug in IBA’s OmniPro-Accept software v7.3-7.4b resulted in water scans in which background 
may not have been subtracted, compressing and offsetting the vertical scale of the data.  
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Unfortunately, it was impossible to be sure which profile measurements were affected by this 
bug.  It follows that some M1 cross-beam profiles had inflated tails.  Ideally, the CS beam 
model would be redone using M2, however such an undertaking is outside of the scope of this 
dissertation.  Furthermore, the CS beam model parameters were not affected by this discrepancy.  
Per-field comparison metrics included (1) absolute percent difference in output factor, 
(2) mean absolute percent global difference in PDD from 0-35cm, (3) mean absolute percent 
local difference in in-field dose, (4) mean absolute percent global difference in out-of-field 
(<10%Dmax) dose, (5) mean absolute distance-to-agreement in the penumbra (80%-20%), (6) 
mean absolute difference in penumbra width, and (7) mean absolute difference in field width 
(50%-50%).  Due to insufficient scan length, penumbra and out-of-field data for the 40x40cm 
field were not analyzed. 
3.2.1.2 Solid Water Phantom Measurement Data – Clinical Fields 
To determine the accuracies of the two calculation methods, point doses measurements were 
taken and compared to both CS and MC calculation.  First, TG-119 measurements were carried 
out.49 TG-119 cases included: prostate, H&N, C-shape (hard), H&N with integrated boost 
(HNSIB), and prostate with lymph nodes (PLN).  It is noted that the latter two cases are 
additional cases provided to us by Henry Ford Health System that are not part of the TG-119 
publication.  HNSIB and PLN were included because they are more difficult than their H&N 
and prostate counterparts and thus push the QA harder.  It is important to QA more difficult 
treatment cases.  Although these two cases are not part of TG-119 for the rest of this chapter 
they will be included as if they are.  Two measurement positions were utilized for each test, one 
at the center of the target ROI and one in an out-of-field organ-at-risk (OAR).  In total, ten 
measurements were compared to ten MC calculations and ten CS calculations.  All 
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measurements were taken using a 0.125cc Wellhofer IC-10 ion chamber inserted into a 
30x30x15cm stack of solid water.  As recommended in TG-119, dose to charge ratio was 
determined by delivering 10x10 AP/PA fields onto the solid water stack and comparing 
measurement to dose calculation.  This dose per charge metric was calculated for both dose 
calculation methods; the difference in the two dose per charge factors was 0.3%.  Finally, results 
were compared to those found in TG-119. 
In addition to the standard TG-119 cases, 11 clinical VMAT plans (22 arcs) were delivered 
onto the same solid water stack.  These plans were selected to cover a range of MC – CS dose 
variations.  Measurement points were selected per plan to be in a high dose, low dose gradient 
regions.  The measurement point was confined to the central 18x18x3cm of the slab to ensure 
6cm of medium to laterally scatter off of at all gantry angles.  The same dose per charge factors 
were utilized as in the TG-119 measurements. For Monte Carlo, the solid water was overridden 
to a density of 1.035. This density was found to maximize the agreement between measurement 
and Monte Carlo for the specific solid water material composition utilized.  A dose grid 
resolution of 4mm was utilized to match the diameter of the ion chamber utilized.  Monte Carlo 
statistical uncertainty was set to 0.25%.  A variety of density overrides were analyzed for 
Convolution Superposition, however, ultimately, utilizing no density override was found to 
yield the greatest agreement between CS and measured doses. 
3.2.1.3 Cork Phantom Measurement Data – Square Fields 
Heterogeneous dose calculation accuracy was assessed for both CS and MC calculation 
with respect to ion chamber measurement in a “lung phantom.”  The lung phantom utilized in 
this study consisted of 10cm of composite cork sandwiched between 6cm (entrance) and 6cm 
(exit) of solid water.  Composite cork is known to be dosimetrically equivalent to ICRU-44 
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lung tissue.91 The solid water slabs on either side of the cork act like the front and back of the 
patient respectively. The phantom was imaged while the ion chamber was inserted into the cork.  
In the resulting CT images, the cork phantom had a mean CT density of -897HU.  To account 
for various ion chamber positions, CT image slices were virtually shifted and re-imported into 
Pinnacle3.  The ion chamber was inserted at 12 depth positions along the central axis after 
accounting for a 1.3mm shift in dose reference point relative to the chamber surface. [1.4, 6.5, 
7.45, 8.4, 9.35, 10.3, 11.25, 12.2, 13.15, 14.1, 16, and 17cm depths]. The ion chamber utilized 
was a TN-34045 parallel plate ion chamber.  Calculation and measurement were compared for 
both 4x4 cm2 and 10x10 cm2 square fields.  Due to the large active volume of the parallel plate 
chamber, smaller field sizes were not investigated. 
3.2.2 LF-MC and LF-CS QA on the Patient Anatomy 
 Log files are acquired using Elekta’s Log File Convertor for Integrity R3.2.  The log 
files record linac delivery parameters (dose rate, gantry/collimator angle, leaf/collimator 
positions, MU) every 40ms.  For this study, an Elekta Infinity linac equipped with the Agility 
beam-limiting device was utilized.  Plans were selected from previously treated patients that 
were planned and optimized using the Pinnacle3 treatment planning system. 
LF QA was assessed on the patient anatomy using both MC and CS dose calculation 
algorithms.  Four dose distributions were utilized in this study.  Plan-CS is the clinical treatment 
plan dose that was planned and optimized in Pinnacle3 v14.0 using convolution-superposition.  
The clinical Plan-CS doses were planned using a 4° control spacing.  Plan-MC is the 
corresponding Monte Carlo dose calculated using the exact same plan as Plan-CS.  LF-CS dose 
is calculated using the linac log file and Pinnacle’s convolution-superposition.  Lastly, LF-MC 
dose is calculated using the linac log file and Monte Carlo.  The log file dose reconstruction 
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methodologies match those explained in chapter 2.  For LF-CS, log files are selected to achieve 
as close to 1° control point spacing as possible.  This is done by converting log file samples into 
control points in a dynamic arc field.  For LF-MC, every log file sample with non-zero MU is 
converted into a control point in a dynamic arc field.  MC doses were calculated using 1% 
statistical dose uncertainty.  CT-to-density table and ROI override information was the same 
for both Pinnacle convolution-superposition (CS) and SciMoCa (MC) dose calculation 
algorithms.  All doses were calculated using the same 3mm dose grid resolution that is used to 
calculate Plan-CS doses clinically at our institution. 
The patient-specific LF-MC QA tool presented in this study is designed to verify the 
accurate calculation and delivery of dose on each patient’s unique heterogeneous anatomy.  
First, accurate dose calculation was verified.  LF-MC QA utilizes three key dose comparisons.  
Comparing Plan-MC to Plan-CS, dose discrepancy resulting from dose calculation method 
differences was isolated.  When comparing dose calculation methods, all comparisons were MC 
with respect to CS.  Comparing LF-MC to Plan-MC, dose discrepancy due to delivery error 
was isolated.  Lastly, LF-MC vs. Plan-CS was analyzed in order to account for the combined 
effects of delivery error and dose calculation.  However, because delivery error was found to 
be near-zero, the combined effects were similar to the effect from the dose calculation 
discrepancy and used for the rest study. 
The LF-CS QA tool presented in this study is simpler than the LF-MC QA tool in that it is 
only capable of catching delivery error; calculation accuracy is not verified.  However, it is not 
as simple as comparing LF-CS to Plan-CS.  In Chapter 2, it was shown that LF-CS QA ought 
to utilize a control point spacing no larger than 2° (1° is preferred).  However, the clinical 
treatment dose, Plan-CS, was calculated with a 4° control point spacing.  Thus, when comparing 
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LF-CS doses to Plan-CS doses, delivery error is not truly being isolated.  In order to assess this 
addition “gantry discretization difference” Plan-CS(4°) control points were linearly interpolated 
in Pinnacle and Plan-CS(2°) dose calculated.  Pinnacle does not easily allow for further 
interpolation, thus Plan-CS(1°) was not calculated.  In total, three doses were compared in order 
to quantify the effects of gantry discretization difference: LF-CS(1°), Plan-CS(2°), and Plan-
CS(4°).  Two comparisons were carried out.  First, LF-CS(1°) dose was compared Plan-CS(4°) 
dose.  This dose difference is due to delivery error as well as gantry discretization differences.  
Second, LF-CS(1°) was compared to Plan-CS(2°).  This dose difference is the same as before 
except with reduced gantry discretization difference.  The goal of studying the effects of gantry 
discretization is to determine if Plan-CS(4°) needs to be interpolated to Plan-CS(2°) for some 
or all LF-CS QA cases.  Whereas clinical Plan-CS dose on the patient anatomy is calculated 
using 4° control point spacing, in Chapter 2 on the ArcCHECK geometry, all Plan-CS doses 
were clinically calculated using 2° control point spacing.  It is important to note that MC does 
not suffer from discretization error.  MC simulates millions of particle histories at all possible 
continuous gantry angles for both Plan-MC and LF-MC.  Thus, LF-MC vs. Plan-MC dose 
difference is an accurate quantification of delivery error.    
 42 patients (85 treatment fields) were selected for this study based on the following 
criteria.  First, plans must have been delivered on the Elekta Agility machine so that linac log 
files could be acquired.  Second, all investigated fields were dynamic arc deliveries.  In total, 
12 head and neck, 6 lung, 6 breast, 5 brain, 4 esophageal, 3 mediastinum, 2 prostate, 2 spine, 1 
stomache, and 1 axillary node patients were analyzed.   
LF-MC QA utilizes the following metrics to evaluate the effects of planned patient dose 
discrepancy.  DVH-based metrics included PTV Dmean, PTV D99%, PTV D95%, and PTV D1%.  
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These metrics were also calculated for GTV ROIs.  Site-specific organ at risk (OAR) constraints 
were utilized as gathered from TG-101 and site-specific RTOG protocols.7 DVH-based metrics 
were evaluated per-plan.  In addition to DVH-based metrics, 3%/2mm gamma pass rates were 
calculated on the patient anatomy using both 10% (standard) and 85% (target approximation) 
dose thresholds.  Lastly, tumor control probabilities (TCP) were calculated per plan as presented 
by Niemierko et al.23 TCP was calculated using GTV when available and CTV when not.  A 
study by Okunieff et al. shows that γ50 values can vary significantly between treatment site.
92 
  Treatment site-specific TCD50 and γ50 values were acquired from a variety of 
publications.92-95 The following treatment site-specific γ50 values were utilized: H&N 1.03; 
brain 0.75; lung 0.57; esophagus 1.03; breast 1.03; mediastinum 0.41; spine 0.41; stomache 
0.71; prostate 0.74.  TCD50 values were selected based upon the staging of each patient’s 
individual treatment.  All LF-MC QA metrics were calculated per-plan. 
3.2.3 Dose Discrepancy (MC vs CS) 
 In Chapter 1, the main sources of calculation difference between Monte Carlo and 
collapsed-cone convolution-superposition were stated as being complexity and heterogeneity.  
Dosimetric differences in the two calculation methods is assessed as a function of beam 
complexity and patient heterogeneity. 
3.2.3.1 Beam Complexity 
Monitor units (MU) per prescription dose (Rx) is a standard metric for quantifying beam 
complexity.96 Variation in dose due to calculation difference was evaluated as a function of 
MU/Rx on the patient anatomy for both target and external (outer contour around the patient 
skin) ROIs. 
3.2.3.2 Patient Heterogeneity 
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Monte Carlo is known to more accurately model anatomical heterogeneities than 
convolution-superposition algorithms.14 To quantify this effect and potentially explain the 
dosimetric variation seen between the two algorithms, 10 patient plans (5 lung and 5 H&N) 
were recalculated with the entire patient volume being overridden to unit mass density.  Dose 
variation was analyzed as a function of tumor position relative to air gaps as well as bony 
anatomies.  
3.3 Results 
3.3.1 Dose Calculation Validation 
3.3.1.1 Water Tank Measurement Data 
Table 8 displays validation results for the two dose calculation methods and two sets of 
measurement data.  From the first two data columns we see that both calculation methods yield 
clinically acceptable results.90 MC consistently agreed within 1% and 1mm of the M2 
measurement data.  Similarly, CS consistently agreed within 1% and 1mm of the M1 
measurement data.  Furthermore, the two sets of measurement data were also in good agreement 
with each other.  The largest difference between the two sets of measurement data was seen out 
of field.  This difference is attributed to a since-fixed software bug in IBA’s OmniPro-Accept 
software where background was not being subtracted despite the software saying it had been.  
M1 contained this bug while M2 did not, resulting in higher tails.  Lastly, MC and CS generally 
agreed within 1% / 1mm of each other.  In comparing the two calculation methods, the greatest 
difference was found to be in the in-field region with a variation of 1%.  Thus, for square-fields 
and a water tank, all measured and calculated data generally agreed within 0.5% or 0.5mm and 
almost always agreed within 1.0% or 1mm.  
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Table 8. Beam model validation results are summarized. *CS output factors are exactly determined from 
measurement. 
 MC vs M2 CS vs M1 M2 vs M1 MC vs CS 
Output Factor 0.15 ± 0.13% 0* 0.25 ± 0.31% 0.25 ± 0.31% 
PDD 0.41 ± 0.17% 0.52 ± 0.13% 0.38 ± 0.19% 0.64 ± 0.28% 
Penumbra DTA 0.23 ± 0.11mm 0.34 ± 0.16mm 0.50 ± 0.89mm 0.45 ± 0.17mm 
Beam Width 0.64 ± 0.62mm 0.60 ± 0.27mm 0.63 ± 0.56mm 0.67 ± 0.32mm 
In-Field 0.58 ± 0.19% 0.60 ± 0.15% 0.24 ± 0.17% 1.06 ± 0.48% 
Out-of-field 0.20 ± 0.16% 0.33 ± 0.41% 0.80 ± 0.09% 0.38 ± 0.25% 
 
3.3.1.2 Solid Water Phantom Measurement Data 
Per-plan percent differences in calculated vs. measured doses for the ten TG-119 
measurement points displayed in Table 9.  Percent differences are normalized relative to the 
prescribed doses.  In general, MC agreement with measurement was superior to that of CS.  CS 
agreed with measurement within 3% for 7/10 cases.  Disagreement as large as -4.6% was seen 
for the in-field C-Shape(Hard) case.  In comparison, MC agreed with measurement within 3% 
for all cases and within 2% for 8/10 cases.   
Table 9. TG-119 results are tabulated per treatment site for both high dose and low dose measurement 
regions as well as both CS and MC dose calculation methods. 
 Percent Difference in Calculated vs. Measured Dose 
 Target Measurement Point OAR Measurement Point 
 CS MC CS MC 
H&N 2.4% 0.9% 4.5% 0.4% 
C-Shape(Hard) -4.6% -1.2% 3.1% -2.7% 
Prostate 0.3% 1.1% 1.7% 2.2% 
Prostate + LN -0.3% 0.9% 1.1% -0.6% 
H&N SIB 1.0% -1.2% -1.3% -1.7% 
 
As displayed in Table 10, TG-119 results found herein are compared to results found in 
the actual TG-119 task group report.  High dose measurements are addressed first.  Whereas in 
TG-119, a confidence level of 4.5% is reported, CS and MC confidence levels were 5.3% and 
2.4% respectively.  Next, low dose TG-119 results were addressed.  Whereas in TG-119, a 
confidence level of 4.7% is reported, confidence limits for CS and MC were 6.1% and 4.2% 
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respectively.  It is important to reiterate that the TG-119 literature results include some simpler 
treatment sites and IMRT deliveries instead of the VMAT deliveries utilized herein.    
Table 10. TG-119 results from this study are compared to literature for both high dose and low dose 
regions. 
 TG-119 CS MC 
 High Dose Region 
Mean Difference -0.2 ± 2.2% -0.2 ± 2.6% 0.1 ± 1.2% 
Mean Absolute 
Difference 
0.9% 1.7% 1.0 % 
Confidence Limit 4.5% 5.3% 2.4% 
 Low Dose Region 
Mean Difference 0.3 ± 2.2% 1.8 ± 2.2% -0.5 ± 1.9% 
Mean Absolute 
Difference 
1.1% 2.3% 1.5% 
Confidence Limit 4.7% 6.1% 4.2% 
 
Per-plan percent difference in calculated vs. measured dose was calculated for eleven 
clinical cases.  On average, MC agreed within -0.04 ± 1.61% of measurement.  Absolute 
agreement was 1.20 ± 1.02%.  In comparison, CS agreed with measurement within 1.65 ± 
1.86%.  Absolute agreement was 1.81 ± 1.69%.  For all but one case (#4), MC agreed with 
measurement within 2%.  CS agreed with measurement within 3% for all but the same case 
(#4).  In general, MC outperformed CS; the MC confidence limit was 3.2% as opposed to the 
5.3% of CS. 
3.3.1.3 Cork Phantom Measurement Data 
 CS and MC calculation were compared to Markus chamber measurement at various 
cork depths in the phantom.  Calculated MC and CS PDDs are plotted against ion chamber 
measurement for 4x4 and 10x10 fields in Fig 13.  On average, CS agreed with measurement 
within 4.3 ± 2.6% and 2.1 ± 1.7% for 4x4 and 10x10 square fields at the measurement points 
shown.  MC agreement was 1.3 ± 1.3% and 0.5 ± 0.4% for the same fields.  Monte Carlo 
67 
 
 
 
agreement with measurement was better than that of CS especially for measurement points 
deeper into the cork.  These results are as expected.  As discussed in Chapter 1, Monte Carlo is 
expected to better calculate heterogeneous dose.   
 
Figure 13. Calculated CS and MC PDDs are calculated and compared to ion chamber measurement in a 
water-cork-water phantom for 10x10 and 4x4 square fields. 
 
 In this section, the dosimetric accuracy of CS and MC was evaluated with respect to 
measurement for square fields as well as clinical VMAT fields as calculated on both a water 
tank and solid water phantom.  The accuracy of these dose calculation methods in a 
heterogeneous environment was also assessed via the use of a heterogeneous cork phantom.  
For square fields in a homogeneous water tank, both CS and MC beam models were both 
accurate within 1% where these values are systematic difference with respect to measurement 
plus one standard deviation.  For square fields in the cork phantom, CS and MC were accurate 
within 2.5% and 1.0% respectively.  For clinical fields delivered on a solid water stack, CS 
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and MC were generally accurate within 3% and 2% respectively.  It is important to note that 
these values are all within the goal of having a 3% dose calculation accuracy.  This 
demonstrates that both dose calculation methods are doing a good job.  Furthermore, it 
demonstrates that the beam models are high quality. 
3.3.2 LF-MC and LF-CS QA on the Patient Anatomy 
Fig. 14 displays histogram plots of variation in PTV Dose.  Subfigure 14a illustrates percent 
variation in calculated dose for the PTV.  Variation in dose due to calculation difference (i.e. 
dose calculation method) is broken down by treatment site and displayed in Table 11.  Subfigure 
14b displays the same data except for delivery error instead of calculation difference.  Dose 
discrepancy due to dose calculation method was substantial.  Percent differences in calculated 
dose for PTV Dmean, D99, D95, and D1 values were -3.4 ± 1.9%, -4.6 ± 2.8%, -4.5 ± 2.1%, and -
1.2 ± 2.8% (negative differences mean MC dose is lower than CS dose).  Variation in GTV/CTV 
dose was generally a relative 5-10% lower than PTV dose variation.  In comparison, dose 
variation due to delivery error was minimal.  Dose variation was consistently within 1% for 
each of the PTV and CTV metrics.  Percent differences in dose due to delivery error for PTV 
Dmean, D99, D95, and D1 were -0.08 ± 0.08%, 0.02 ± 0.2%, 0.01 ± 0.12%, and -0.15 ± 0.17%.   
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Figure 14. Histogram plots of percent difference in key PTV DVH metrics as a result of a) calculation 
difference, b) delivery error. 
 
Table 11. Target and OAR dose variation due to calculation difference (MC – CS) is quantified per 
treatment site.  Absolute dose difference is in units of Gy.  The number of patients per treatment-site are 
shown in parentheses. 
 
Per-plan 3%/2mm gamma pass rates were calculated on the patient anatomy using both 
10% (standard) and 85% (target region) dose thresholds.  Isolating delivery error, every pass 
rate was greater than 99%.  Isolating calculation difference, the 42 per-plan gamma pass rates 
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were 87 ± 12% and 55 ± 27% for 10% and 85% thresholds respectively.  The distribution of 
gamma results are shown in Fig. 15.  Given the poor agreement in PTV Dmean dose between CS 
and MC in Fig. 14a, these poor gamma passing rates are expected.  
 
Figure 15. Histogram plot of 3%/2mm gamma pass rates (Plan-MC vs. Plan-CS) using both 10% and 85% 
dose thresholds. 
 
 Clinical per-beam 3%/2mm ArcCHECK gamma passing rates were compared to a 
variety of per-beam LF-MC QA metrics as calculated on the patient anatomy.  These metrics 
included PTV Dmean, PTV D99, PTV D95, and PTV D1 as well as 3%/2mm gamma calculated 
using 10% and 85% thresholds.  Using a linear fit, R2 correlations were drawn both when 
delivery error and calculation differences were isolated.  When isolating delivery error (LF-MC 
vs. Plan-MC), R2 values were all near zero.  AC gamma pass rates had no correlation with 
delivery-error-only LF QA metrics as calculated on the patient’s anatomy.  Isolating calculation 
difference (Plan-MC vs. Plan-CS), R2 values were small, but non-negligible.  PTV Dmean 
yielded an R2 correlation of 0.24 with respect to AC passing rate.  The other PTV metrics had 
correlations of 0.12-0.14 while the gamma metrics were 0.05-0.08.  AC gamma pass rates were 
largely uncorrelated with both gamma-based and DVH-based LF QA metrics on the patient’s 
anatomy.  It is the goal of radiotherapy to delivery accurate dose on the patient’s anatomy.  This 
71 
 
 
 
disconnect between AC QA results on the phantom geometry and LF QA results on the patient 
geometry suggest that AC QA is simply not capable of detecting clinically relevant dosimetric 
errors as calculated on the patient anatomy. 
 Difference in TCP (TCPPlan-MC - TCPPlan-CS) was on average -3.1 ± 1.8%.  Out of 42 
plans, 29/18/13/6/3 plans had drops in TCP greater than 2/3/4/5/6%.  A histogram plot of the 
per-plan decrease in TCP as measured using LF-MC QA is displayed in Fig. 16.  The 
significance of this drop in TCP is discussed later, however, suffice it to say for now that these 
are fairly significant drops in TCP. 
 
Figure 16. A histogram plot displaying reduction in TCP (Plan-MC vs. Plan-CS). 
 
Gantry discretization difference, illustrated in Fig. 17, was assessed for LF-CS QA.  
Subfigure 17a displays the effects of gantry discretization difference (LF-CS(1°) vs. Plan-
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CS(4°)) on various PTV DVH metrics.  Subfigure 17b displays the same values except for 
reduced gantry discretization difference (LF-CS(1°) vs. Plan-CS(2°)).  Dose variations for LF-
CS(1°) vs Plan-CS(4°) were 0.45 ± 1.95%, 0.14 ± 0.96%, and 2.63 ± 4.07% for PTV Dmean, D99, 
and D1 respectively.  Dose variations for LF-CS(1°) vs Plan-CS(2°) were 0.0 ± 1.99%, 0.20 ± 
1.16%, and 0.67 ± 1.12%.  Utilizing Plan-CS(2°) instead of Plan-CS(4°) resulted in reduced 
dose differences.  Mean PTV Dmean dose difference decreased from 0.45% to 0.0%.  Mean PTV 
D1 dose difference decreased from 2.63% to 0.67%.  These results show that the dosimetric 
difference due to gantry discretization is typically on the order of 0-2%, however PTV D1 
differences as large as 4% are possible for more severe cases.  Although a 0.5% difference in 
PTV Dmean is not hugely significant, this dose difference is large with respect to dose difference 
due to delivery error.  Thus, it is the recommendation of this study that Plan-CS(4°) be 
interpolated to Plan-CS(2°) when carrying out LF-CS QA. 
 
Figure 17. Histogram plots of percent dose difference in key PTV DVH metrics as a result of a) gantry 
discretization difference and b) reduced gantry discretization difference. 
 
3.3.3 Dose Discrepancy (MC vs CS) 
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In section 3.1, both dose calculation algorithms were shown to be accurate within 3%, 
however, when dose is calculated and compared on the patient anatomy in section 3.2, 
significant dosimetric differences greater than this 3% were seen.  Thus, the cause of this 
difference was investigated within the scopes of beam complexity and patient heterogeneity. 
3.3.3.1 Beam Complexity 
Variation in PTV Dmean, PTV D99, GTV Dmean, and GTV D99 with respect to MU/Rx yielded 
R2 correlations of 0.35-0.41.  R2 correlation for the external ROI was 0.67.  These correlations 
suggest a significant portion of LF-MC QA dose discrepancy as calculated on the patient 
anatomy is due to beam complexity.  GTV D99, the target ROI with the greatest correlation 
value, is plotted against MU/Rx in Fig. 18.  As displayed in Table 12, variation in GTV D99 
was investigated for simple (< 3.5 MU/Rx) plans and complex (> 3.5 MU/Rx) plans.  For simple 
plans, ΔGTV D99 was -3.89 ± 1.92%.  Dosimetric variation was greater for the complicated 
plans; ΔGTV D99 was -6.64 ± 1.97%.   
 
Figure 18. Per-plan Percent variation in GTV D99 (MC – CS) is plotted as a function of the beam 
complexity MU/Rx. 
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Table 12. Dose discrepancy is evaluated for simple (MU / Rx < 3.5) and complicated (MU / Rx > 3.5) 
patient cases. 
Metric (MC – CS) 27 Simple Cases  15 Complex Cases  
ΔGTV D99 -3.9 ± 1.9 -6.6 ± 2.0 
ΔPTV D99 -3.7 ± 2.2% -6.4 ± 2.6% 
ΔTCP -2.7 ± 1.6% -3.9 ± 1.9 
 
Variation in TCP with respect to MU/Rx yielded an R2 correlation of 0.15.  For the 27 
simple plans, ΔTCP was -2.57 ± 1.70%.  For the 15 complicated plans, ΔTCP was even greater 
at -3.94 ± 1.89%.  The low correlation between TCP and MU/Rx is to be expected.  Above, 
GTV D99 was shown to have a 0.42 R
2 correlation with MU/Rx.  All other DVH metrics had 
lower R2 values.  It follows that TCP, which is one step further removed from MU/Rx, will thus 
have an R2 values lower than 0.4.  In addition, we know that ΔTCP is proportional to Δ(dose 
difference) multiplied by γ50 in the central non-shoulder part of the dose response curve.  
However, the 42 cases studied all have varying values of γ50.  This will result in even further 
reduced values of correlation between TCP and MU/Rx. 
3.3.3.2 Patient Heterogeneity 
Displayed in Fig. 19, per-plan percent difference in PTV Dmean was calculated for both 
the heterogeneous patient anatomy, as well as when the anatomy was fully overridden to unit 
density.  Heterogeneity was evaluated per-site for two treatment sites with greater heterogeneity 
- lung and H&N.  Five lung and five H&N plans having a range of dose calculation agreement 
were selected.  For the five H&N patients, MC – CS agreement was actually poorer on the 
homogeneous anatomy.  Dose agreement decreased by 10 ± 23% when overriding the patient 
to water.  This indicates heterogeneity effects were largely insignificant for the H&N cases.  
For the five lung patients, MC – CS agreement was better for four of them on the homogeneous 
anatomy.  On average the dose variation was 18 ± 21%.  This indicates ~20% of the lung dose 
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variation due to calculation differences was due to heterogeneity effects.  CS dose variation 
with respect to MC was mostly seen at the outer surface of higher density tumor voxels proximal 
to low density lung tissue.  This over estimation of target dose by CS is likely due to poor 
estimations when it comes to loss of lateral scatter equilibrium in low density media.16   
 
Figure 19. Per-plan percent difference in PTV Dmean due to dose calculation difference is displayed. 
 
3.4. Discussion 
LF-MC QA yielded PTV Dmean and PTV D99 dose discrepancies greater than 5% for 14% 
and 40% of patients respectively.  The clinical impact of this discrepancy is best evaluated 
within the scope of TCP as no other metric can as succinctly quantify the effectiveness of a 
treatment plan.  Decrease in TCP, calculated using GTV, was on average -3.1 ± 1.8%.  Out of 
42 plans, 29/18/13/6/3 plans had drops in TCP greater than 2/3/4/5/6%.  The effect of these 
drops in TCP can best be evaluated in terms of recurrence rates.  By definition, TCP quantifies 
the probability that 0 clonogenic cells survive the radiotherapy treatment.  However, it is not 
necessary to kill every clonogenic cell.  In reality, only enough cells need to be killed that the 
76 
 
 
 
re-development of a symptomatic tumor is prevented for the remaining duration of the patient’s 
life.  This relapse time, or time at which a symptomatic tumor is expected to return, can be 
calculated via Eq. 13, where G(t) is the probability of recurrence at time t, Pm is the probability 
𝑮(𝒕) = ∑ 𝑷𝒎[𝑮𝟏(𝒕)]
𝒎∞
𝒎=𝟎            (14) 
that m number of clonogenic cells remain after radiotherapy, and G1(t) is the probability that a 
clonogenic cell does not become a symptomatic tumor at time t.15 For example, given a decrease 
in TCP from TCPPlan-CS to TCPLF-MC, a new probability distribution function detailing the 
probability of m number of clonogenic cells surviving can be calculated.  Subsequently a new, 
higher, probability of recurrence at time t can be calculated.  Following this train of thought, 
allowable decrease in TCP is really a patient-specific problem.   
 Despite substantial dose disagreement as determined using LF-MC QA on the patient 
anatomy, ArcCHECK QA results were consistently passing.  LF-MC QA dose discrepancy 
stemmed primarily from dose calculation method.  Values of PTV Dmean and PTV D99 were -
3.4 ± 1.9% and -4.6 ± 2.8% lower for MC than CS for the 42 patient cases.  77/7/1 fields had 
pass rates of 95-100%/90-95%/87%.  Furthermore, DVH-based LF-QA results were largely 
uncorrelated with clinical AC gamma pass rates.  It follows that the coefficients of 
determination between the LF-MC QA results and gamma results were quite low.  PTV Dmean 
displayed the greatest correlation with clinical 3%/2mm gamma passing rates with an R2 of 
0.24.  All other LF QA metrics had R2 values less than 0.14.  Discrepancy in LF-MC QA and 
AC QA results can be attributed to several factors.  Foremost is the mismatch in geometries 
utilized.  A homogeneous, symmetric cylindrical phantom is not representative of the patient’s 
anatomy.  The phantom will not be able to account for patient-specific heterogeneities.  In 
addition, when delivering IMRT planned doses which have been optimized on the patient’s 
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anatomy onto a different geometry (e.g. ArcCHECK), the uniform target dose is blurred across 
a greater region.  Simultaneously, the dose difference (e.g. MC vs. CS) is spread out over a 
greater volume, resulting in lower local percent variations in dose.  This percent dose variation 
is further decreased when utilizing a global dose criteria (e.g. Van Dyke).  Lower dose variance 
will yield higher gamma pass rates.  Lastly, the diode detectors are placed at a fixed depth that 
likely does not correspond to the target location.  If follows that the diode measurements are 
not as applicable as they maybe ought to be.   
 The failing AC QA result was addressed.  The case was a four arc VMAT H&N case.  
Of the four arcs, one yielded an ArcCHECK pass rate (Plan-CS vs. AC) of 87.2%.  Comparing 
Plan-MC to AC, a 3%/2mm gamma pass rate of 92.3%.  Upon further investigation it was 
determined that this failure resulted from delivery error.  By reconstructing LF-CS dose on the 
ArcCHECK geometry, an LF-CS vs. AC passing rate of 100% was calculated.  Similarly, LF-
MC vs. AC also yielded a 100% passing rate on the ArcCHECK geometry.  Digging into the 
log file, this delivery error was determined to result from the non-linear delivery of MU/degree 
as well as gantry error up to 1.4 degrees.  Importantly, this non-linearity in MU/degree 
coincided at the same gantry angle as where the gantry error occurred.  When dose is calculated, 
MU output is assumed to be linearly delivered between control points, however, this is not 
always the case.  The ArcCHECK failure pattern which was caused by this delivery error is 
circled in Fig. 20.  Fig 21 and Fig. 22 display the non-linear MU/degree output and gantry error 
respectively.  Despite this delivery error and low 3%/2mm gamma passing rate, dosimetric 
discrepancy due to delivery error on the patient anatomy was minimal; variations in PTV Dmean 
and PTV D99 were -0.7 and -2.6% respectively.  This demonstrates that delivery errors as 
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measured on the ArcCHECK phantom do not necessarily translate into DVH-based errors on 
the patient anatomy. 
 
Figure 20. An ArcCHECK failure pattern for Plan-MC vs. AC resulting from gantry error and non-linear 
MU/° is shown.  
 
Figure 21. MU/° is plotted as a function of gantry angle. 
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Figure 22. Gantry error is plotted as a function of gantry angle. 
 
Dose discrepancy due to delivery error was extremely small for all cases studied.  Delivery 
error peaked at 0.8% of the fractional prescribed dose and was typically within a few tenths of 
a percent.  In comparison, despite excellent square-field water tank validation results, dose 
discrepancy due to dose calculation method was large.  This disagreement was investigated 
within the scopes of tissue heterogeneity and beam complexity.  The effect of tissue 
heterogeneity was greatest for lung tumors; 20% of dose discrepancy was explainable by 
heterogeneity effects.  However, heterogeneity did not play a significant role for other treatment 
sites.  In comparison, 40% of dose discrepancy was explainable by beam complexity over all 
treatment cases.  Table 12 shows that dose discrepancies were much greater for the complicated 
(MU / Rx > 3.5) treatment cases.  These results were investigated within the scope of treatment 
planning QA – “Given these results, is there some way this dose difference can be mitigated?”.  
CS and MC inherently model tissue heterogeneities differently.  CS is not designed to 
accurately account for inhomogeneities, thus little can be done to mitigate these calculation 
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differences.  However, when it comes to beam complexity, action can be taken to reduce beam 
complexity.  The most obvious method is to increase the minimum leaf pair gap that can utilized 
for VMAT treatment.  This will result in smaller MU/Rx values, and thus should result in 
greater CS dose calculation accuracy.  At out clinic a minimum leaf gap spacing of 6mm is used 
for VMAT treatment planning.  However, several studies have recommended that minimum 
leaf gap spacings should be set to ≥2cm to minimize variation in calculated and measured 
dose.102-104 Difference in MC and CS IMRT/VMAT dose is largely attributed to this difference. 
Monte Carlo beam models may not always be available for every institution, machine, 
and/or energy.  Thus, LF-CS QA was also evaluated.  Specifically, CS gantry discretization 
difference was assessed.  Assuming LF-MC vs Plan-MC to be the gold standard for estimating 
delivery error, dose variations for PTV Dmean, D99, and D1 were a very small 0.11 ± 0.10%, 0.12 
± 0.11%, and 0.20 ± 0.18%.  However, comparing LF-CS to Plan-CS, dose variation could be 
large due to gantry angle discretization.  Comparing Plan-CS(4°) to LF-CS(1°), PTV Dmean and 
D1 dose variations were 0.5 ± 2.0% and 2.6 ± 4.1%.  Linearly interpolating Plan-CS(4°) to Plan-
CS(2°), dose variation with respect to LF-CS decreased to 0.0 ± 2.0% and 0.7 ± 1.1% 
respectively.  Using 2 degree control point spacing, LF-CS QA is capable of verifying delivery 
error within fairly tight bounds; Plan-CS PTV metrics were generally accurate within 1% of 
LF-CS(1°) and almost always accurate within 2%. 
MC agreement with measurement was superior to that of CS.  In-field and out-of-field, MC 
confidence limits were 2.4% and 4.2% respectively.  In comparison, CS confidence limits were 
6.3% and 6.1%.  Across all 10 institutions in TG-119, confidence limits were 4.5% in-field and 
4.7% out-of-field.49 However, whereas much of the data acquired in TG-119 is for IMRT cases 
and simpler treatment sites, the VMAT cases utilized in this TG-119 study were relatively more 
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complicated.  This increased complexity is hypothesized to result in the higher CS confidence 
limit.  However, given the ±5% dose goal, the 6% CS confidence limits are somewhat 
unacceptable.  In comparison, the MC confidence limits, especially in-field, were very good. 
Three methods are introduced for addressing the aforementioned decreases in dose and 
tumor control.  First, it may be preferable, once the computational cost of Monte Carlo is 
sufficiently low, to simply utilize a TPS that utilizes MC in the plan optimization process.  
Second, the planned number of MU could be simply scaled by a scaling factor, SF = CS PTV 
D99 / MC PTV D99.  Third, the direct machine parameter optimization (DMPO) process could 
be constrained.  For example, many of the worst cases in this study were highly complicated 
H&N or breast cases.  An investigation into aperture shape revealed many segments with thin 
(< 1cm) snake-like apertures.  Increasing the minimum dynamic leaf pair gap in the Pinnacle 
TPS should yield simpler beam segments and thus smaller ΔTCP values.  
LF-MC QA is intended to fully replace conventional phantom-based QA systems.  As such, 
new protocols are required to determine whether the results of LF-MC QA on the patient 
anatomy should be considered passing or failing.  Initially, a |ΔTCP D99| < 4% action tolerance 
was investigated.  This tolerance was selected given that dose calculation methods are typically 
expected to be accurate within 3-4%.19 However, this resulted in a 41% failure rate.  Given 
clinical workload constraints, the number of failing cases should not be more than 10%.  
Investigating various criteria, an action tolerance of |ΔPTV D99| < 5% and |ΔTCP| < 4% was 
decided upon.  Using this criteria, 8/42 cases failed.  However, of these eight cases six were 
complicated fields (MU/Rx > 3.5).  Given the dependence of dose discrepancy on beam 
complexity, it is the recommendation of this study that physicists/dosimetrists attempt to limit 
MU/Rx < 3.5 if using CS or an equivalent algorithm.  With a total of 27 simple cases, the 
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remaining 2 failures represents a 7% failure rate.  For these failures it is the recommendation 
that the prescription dose to the patient be multiplied by the aforementioned scaling factor, SF, 
and that the plan be re-optimized.   
In general, OAR dose discrepancies were less significant than target dose discrepancies.  
This was largely due to MC calculation being systematically lower than CS.  As negative OAR 
discrepancies will result in lower normal tissue complication probability (NTCP) values, 
negative discrepancies were not assessed. Variation in OAR dose due to calculation difference 
was assessed using 1Gy/3%, 2Gy/3%, and 3Gy/3% passing criteria.  Over the 42 plans analyzed 
in this study, roughly 1000 dose-volume constraints were QAed.  Of these 1000 constraints, 19 
failed using a 1Gy/3% criteria.  Of these failures, 12 failures were for Cochlea D1%; mean 
variation was 3.9 ± 1.8Gy.  The remaining failures included brain stem, oral cavity, esophagus, 
bladder, penile bulb, brachial plexus, and mandible ROIs receiving 1.04, 1.21, 1.18, 1.05, 1.07, 
2.18, and 3.83Gy more dose via MC than CS.  Variation in OAR dose due to delivery error was 
assessed using a 0.5Gy/1% criteria.  Of the 1000 dose-volume constraints, there was one failure; 
a cochlea D1 varied by 0.7Gy/5%.  Although a couple of these dose discrepancies were 
moderately large, the previously analyzed variations in target dose were more significant.  Thus, 
given workload constraints, none of these variations were considered significant enough to label 
LF-MC QA as failing. 
Although MC and CS calculation typically matched measurement within 2% and 3% 
respectively in a homogeneous media, calculation matched measurement poorly for a subset of 
the TG-119 & clinical VMAT cases.  This trend is similar to what was shown by Bouchard et 
al.98 Out of 1600 IMRT measurements in a phantom, 1300 agreed within 2%. Calculation 
disagreement ranged from -12.7% to 11.7% for the other 300 cases.  It is important to note these 
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measurements were taken using the same size ion chamber as utilized herein.  However, for 
this size ion chamber, correction factors for dynamic IMRT fields can be greater than 10%.59 
This suggests that any disagreement between calculation and measurement for IMRT/VMAT 
fields in this study could very well be due to measurement inaccuracy.   
 Comparing Plan-MC to Plan-CS, dose discrepancy was assessed as a function of 
heterogeneity, beam complexity, and gantry discretization.  PTV Dmean dose discrepancy 
stemmed ~10% from heterogeneity, ~40% from beam complexity (MU/Rx), ~10% from gantry 
discretization, and ~40% from unknown sources.  However, it is important to understand that 
these values are approximations.  First, MU/Rx, although a simple and apt metric for indicating 
beam complexity, is simply an approximation of beam complexity.  Second, overriding the 
patient anatomy to water, although a good experiment for assessing the effect of heterogeneity, 
is not simple to quantify.  It follows that some additional fraction of the unexplained variance 
is likely due to beam complexity and/or heterogeneity. 
3.5 Conclusion 
Delivery errors, as tracked from linac log files, as well as calculation differences 
(ScientificRT’s SciMoCa Monte Carlo vs. Pinnacle’s Convolution-Superposition) were 
assessed on patient anatomies.  Differences in DVH metrics due to delivery error were typically 
on the order of a couple tenths of a percent, indicating delivery errors for the Elekta Infinity 
linac equipped with an Agility treatment head were very minimal.  Dosimetric difference due 
to gantry angle discretization error was moderate.  When using LF-CS QA, Plan-CS should be 
interpolated to ≤ 2° control point spacing.  Whereas phantom-based AC QA was consistently 
passing, LF-MC QA was able to catch clinically worrisome dose discrepancies as calculated on 
the patient’s anatomy.    Percent differences in PTV Dmean, PTV D99, and TCP as large as 7%, 
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10%, and 7% on the patient anatomy.  Reductions in TCP as large as 7% were also calculated.  
Dose discrepancy was primarily due to beam complexity.  For instance, when using an action 
tolerance of [|ΔGTV D99| < 5% and |ΔTCP| < 4%] for patient anatomy-based planning QA, 7% 
of simple (MU/Rx < 3.5) cases and 53% of complicated (MU/Rx > 3.5) cases failed.  Thus, it 
is recommended that treatment planning beam complexity be constrained within MU/Rx < 3.5 
if dose is calculated using CS of an equivalent algorithm.  It is concluded that, given proper 
machine QA and Monte Carlo commissioning, anatomical LF-MC QA is a fully automatable 
technique with the potential to fully replace phantom-based QA techniques.   
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CHAPTER 4 LF QA SOFTWARE 
 LF QA software was developed alongside the aforementioned research.  Fig. 23 
illustrates the general architecture of LF QA.  There is a central LF QA server that is in charge 
of LF QA.  The server receives log files from a linac or linacs.  It queries Mosaiq to match a 
log file to the correct patient.  It is connected to a linux server dedicated for the management 
and calculation of Monte Carlo doses.  Lastly, it’s setup so that one or multiple physicists’ 
computers can easily initiate LF QA and analyze the results in Pinnacle.  The LF QA software 
consists of three main components: (1) a system for automatically archiving log files in a 
manner where log files can easily be acquired when required; (2) LF-CS QA; and (3) LF-MC 
QA.  Fig. 23 illustrates the key systems of LF QA.   
 
Figure 23. Log File QA Workflow.  A central log file server acquires the log files from the linacs, matches 
the log files to a patient’s plan using Mosaiq, calculates dose using SciMoCa, and pushes the resultant dose 
to Pinnacle for evaluation. 
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4.1 Log File Acquisition & Storage 
 First, acquisition of log files is discussed.  Ideally, log files should be pushed to a log 
file server immediately upon the delivery of the field.  This would allow the log file to be 
processed and log file dose to be calculated as soon as possible.  Unfortunately, this method is 
not provided by Elekta.  Thus, Elekta log files were acquired using the following two methods.  
First, log files can be manually exported by the physicist by putting the linac into service mode.  
This process takes roughly 10 minutes.  The exported file is a zip file which contains per-field 
log files in binary .trf format.  This export includes log files from the last 8 days.  The benefit 
of this method is log files can be acquired and pushed to the log file server for processing in 10 
minutes.  The disadvantage of this method is that it requires the physicist to manually export 
log files. The second method used to acquire log files is routine and automatic, but not quick.  
The linac hard disk (specifically, the D: drive) is backed up to a set location on a weekly basis.  
Both manually exported and weekly automatically exported log files are sent to the same 
location.  The log file server is setup to monitor this location and process files when they are 
acquired.  For the weekly linac snap shots, the disk image is programmatically mounted as a 
virtual share drive.  The log files (.trf) are then acquired from the share drive and the disk image 
is unmounted. 
 Binary trf files are then converted into ASCII .csv files.  Unfortunately, the log file 
contains limited information as it pertains to patient and/or beam identification.  However, we 
do know when the beam was delivered and on what machine.  By querying Mosaiq this is 
enough information to determine what patient this log file is for, as well as which treatment 
plan and which treatment field, etc.  Log files, both trf and csv, are then stored in a directory of 
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the following format: Database / MachineName / PatientID / TreatmentName / DeliveryDate / 
FieldID.  A PostgreSQL database is setup to store information about all relevant log files. 
4.2. LF-CS QA 
 LF-CS QA is carried out on the patient’s anatomy using the methods described in 
previous chapters.  The csv log file is converted into a Pinnacle script that in turn creates a plan 
in Pinnacle.  From here, dose is calculated and analyzed in Pinnacle.  This is a semi-automatic 
process.  From the LF QA software, the physicist selects which fields they want to reconstruct 
log file dose for.  This spawns a program which converts the log files of interest into two 
pinnacle scripts which are sent to the Pinnacle server.  The physicist then opens Pinnacle, runs 
the first script (initialize beams and control points), runs the second script (sets beams to match 
the log file samples), and calculates dose.  Pinnacle scripting is not particularly quick.  
Converting 358 log file samples into 358 control points for a 358° VMAT arc (1° control point 
spacing) can take close to an hour.  Dosimetric analysis of the reconstructed log file(s) in 
Pinnacle is left to the discretion of the physicist. 
4.3. LF-MC QA 
LF-MC QA is initiated in the same way as LF-CS QA.  The physicist selects which fields 
they want to reconstruct LF-MC doses for and clicks ‘Run LF-MC QA’ in the GUI.  This 
spawns a program on the LF QA server.  This program first queries a PostgreSQL database that 
contains path locations for each beam / trial in Pinnacle.  The query returns a full path location 
on the Pinnacle server.  From this location, a variety of Pinnacle files are acquired and converted 
into DICOM format.  Monte Carlo calculation is carried out using these DICOM files (CTs, 
RTSTRUCT, RTPLAN).  This process then converts the MC doses (Plan-MC, LF-MC) into 
binary Pinnacle format and creates a Pinnacle script to load the doses into Pinnacle.  In total, 
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this process typically takes ~10 minutes.  SciMoCa dose calculation usually takes ~2 minutes 
per VMAT arc using a 3mm dose grid and 1% statistical uncertainty.  Fig. 24 shows the client 
GUI that physicists can use to automatically carry out Plan-MC and LF-MC doses as part of 
LF-MC QA.  Fig. 25 shows a sub-GUI that is utilized to export doses to Pinnacle for further 
evaluation. 
 
Figure 24. LF QA GUI for calculating Plan-MC and LF-MC doses.  Doses can also be exported to a separate 
tool which is utilized for LF-CS QA. 
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Figure 25. GUI for selecting doses to export to Pinnacle for evaluation. 
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CHAPTER 5 CONCLUSION 
Accurately reconstructing dose on each patient’s unique anatomy, LF-MC QA has shown 
great potential for patient-specific QA.  Using Monte Carlo, dose calculation accuracy was ~1.2% 
(1σ) and generally within 2% for complex VMAT fields delivered on a homogeneous solid 
water stack.  In addition, SciMoCa was shown to be able to accurately calculate dose in a 
heterogeneous cork phantom within 2%.  In comparison, this study has shown conventional 
phantom-based QA to be generally lacking.  In Chapter 2, diode sensitivity dependence on dose 
rate, beam complexity, and energy was investigated.  Diode sensitivity varied up to 1.5% in-
field with dose rate and up to 5% out-of-field with energy.  Phantom-dependent uncertainties 
were on average 0.8 ± 1.2%.  In Chapter 3, ArcCHECK gamma passing rates were consistently 
passing even though DVH differences ≥5% were calculated using LF-MC QA on the patient 
anatomy.   In follows that AC pass rates were  uncorrelated with both DVH-based and gamma-
based LF-MC QA metrics as calculated on the patient anatomy (R2 < 0.24).  Finally, even when 
the ArcCHECK phantom registered a poor passing rate due to the combined effects of gantry 
error and non-linear MU, these delivery errors negligibly impacted anatomical DVHs.  It is 
therefore the conclusion of this study that ArcCHECK, and perhaps phantom-based QA systems 
in general, is not an ideal method of patient-specific treatment plan QA.  In comparison, LF-
MC QA was able to not only accurately determine the delivered dose distribution on the patient, 
but also accurately determine the cause of potential dose differences.  In addition, this QA 
technique also provide a possibility for online or real-time planning modification/treatment. 
Despite the significant advantages of LF-MC QA over AC QA, there exist strict 
requirements that LF-MC QA must abide by.  The two primary requirements of LF QA are that 
it relies on reliable machine QA and an accurate dose calculation method.  The 6MV SciMoCa 
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Agility beam model utilized as part of this study was shown to accurately calculate dose within 
2-3% for both heterogeneous anatomy and complicated MLC segments.  However, it is 
essential that each institution thoroughly vet each of their MC beam models.  LF-MC QA also 
relies on proper machine QA. Variations in output and beam tuning are not monitored via log 
files and thus must be sufficiently monitored via machine QA.  In addition, MLC calibration 
must be maintained.  However, these disadvantages are addressable – strictly maintain machine 
QA and/or expand upon current machine QA protocols.  In conclusion, although LF-MC QA is 
not flawless, it is a superior form of patient-specific QA to AC QA. 
LF QA on the phantom geometry yielded equivalent results as AC QA.  It follows that LF 
QA on the phantom geometry can fully replace AC QA.  Furthermore, LF QA on the phantom 
geometry allows for root cause of analysis of any potential delivery errors.  However, given 
concerns with phantom-based QA in general, neither ArcCHECK QA nor LF QA as calculated 
on the phantom geometry are recommended forms of QA.    
A benefit of this study and the benefit of LF-MC QA is that it is immediately clinically 
impactful.  This study was immediately clinically impactful at our institution as well.  This 
study showed us that machine delivery error is very small and generally clinically negligible 
for our Elekta Agility machine.  Instead dose calculation was shown to be extremely 
important.  Investigating dose calculation further, it was found that complexity was the 
primary concern of dose calculation accuracy at our institution.  As a result, we changed our 
minimum leaf gap in our treatment planning system to be 1.5cm instead of 0.6cm.  We also 
notified our dosimetrists that plans should ideally be within 3.5 MU / Rx.  The greatest 
clinical takeaway from this study is that ArcCHECK QA and perhaps phantom-based QA is 
largely irrelevant.  ArcCHECK QA was incapable of catching clinically relevant dosimetric 
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errors as determined via LF-MC QA on the patient anatomy.  Thus, despite being the standard 
of care for decades, ArcCHECK absolutely should not be the primary form of patient-specific 
QA in clinics.  In comparison, Elekta LF-MC QA has no real weaknesses.  LF QA relies on 
accurate dose calculation, but Monte Carlo has been shown to be very accurate given proper 
beam modeling.  LF QA also relies on accurate machine QA, but it is not the responsibility of 
patient-specific QA to reconfirm accurate machine QA.   
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ABSTRACT 
UTILIZING LOG FILES FOR TREATMENT PLANNING AND DELIVERY QA IN 
RADIOTHERAPY 
 
by 
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Major: Medical Physics 
Degree: Doctor of Philosophy 
Purpose: Monte Carlo-based log file quality assurance (LF-MC QA) is investigated as 
an alternative method to phantom-based patient-specific quality assurance in radiotherapy (e.g. 
ArcCHECK QA (AC QA)).   
Methods: First, the shortcomings of AC QA were investigated.  The sensitivity 
dependence of ArcCHECK diodes on dose rate (in-field) and energy (primarily out-of-field) 
was quantified.  LF-MC QA was then analyzed on the phantom geometry.  Planned (‘Plan’) 
and LF-reconstructed CS and MC doses were compared with each other and AC measurement 
via statistical (mean ± StdDev(σ)) and gamma analyses to isolate dosimetric uncertainties and 
quantify the relative accuracies of AC QA and LF-MC QA.  LF-MC QA was then analyzed on 
the patient geometry.  Calculation algorithm dependent (Plan-MC vs Plan-CS) and delivery 
error (LF-MC vs Plan-MC) dependent dosimetric discrepancies were isolated.  Dose 
discrepancies were evaluated using PTV Dmean, D99, and D1 as well as tumor control probability 
(TCP).  Dose discrepancy due to calculation algorithm was further assessed as a function of 
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heterogeneity and beam modulation complexity (MU/Rx).  LF QA results were compared to 
clinical AC QA results.  Various LF-MC QA pass/fail protocols were assessed. 
Results: Calculation and ArcCHECK measurement differed up to 1.5% in-field due to 
variations in dose rate and up to 5% out-of-field due to energy effects.  On the ArcCHECK 
geometry, phantom-dependent, calculation algorithm-dependent (MC vs. CS), and delivery 
error-dependent dose uncertainties were 0.8±1.2%, 0.2±1.1%, and 0.1±0.9% respectively.  On 
the patient anatomy, percent differences in [PTV Dmean, D99, D1] were [-0.1±0.1%, 0.0±0.2%, -
0.2±0.2%] for machine delivery error, [-3.4±1.9%, -4.6±2.8%, -1.2±2.8%] for dose calculation 
difference, and [0.5±2.0%, 0.2±1.2%, 2.6±4.1%] due to limited VMAT beam sampling.  Drop 
in TCP due to calculation difference (MC-CS) was -3.1±1.8% [min -5.7%].  41% of PTV D99 
dose calculation difference was due to beam complexity.  Heterogeneity effects were negligible 
for H&N.  For lung, 18% of dose calculation difference on PTV Dmean was due to 
heterogeneity   
Conclusions: ArcCHECK QA was consistently incapable of catching clinically relevant 
dose discrepancies as calculated on the patient anatomy using LF-MC QA.     
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